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Over one million total hip replacements (THRs) are performed worldwide every year and in general, 
provide cost effective pain relief and improved function for people with end-stage osteoarthritis (OA). 
Given time, all THRs will fail and many of those that do require revision surgery, which is costlier 
and less effective than the primary operation. Many different THR prostheses are available and 
variation in their survival has been observed. This thesis aims to predict the long-term (greater than 
15-year) revision rate of THRs using the Princess Elizabeth Orthopaedic Centre, Exeter (PEOC) local 
database and the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man 
(NJR) to help inform minimum acceptable performance standards (benchmarks). 
The revision rate of THRs from PEOC was compared to the to the rest of the country using NJR data 
to prove generalisability of survival results from PEOC. A predictive algorithm adjusting for age and 
gender was developed, based on the PEOC database, using flexible parametric survival analysis and 
then applied to the NJR dataset as an out of sample estimate. 
The predicted revision rate, for the contemporary prostheses combinations used in PEOC, after 10 
years was 2.2% (95% CI 1.8, 2.7) which was validated by NJR data. An extrapolated prediction at 30 
years suggests an all cause revision rate of 6.5% (95% CI 4.5, 9.4). 
The predicted revision rate for these prostheses combinations after 10 years is well below the 5% 
revision benchmark currently set by the National Institute for Health and Care Excellence (NICE). 
This thesis supports lowering of the existing benchmark and extending it past 10 years to ensure as 
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Chapter 1 Introduction  
1.1 Total Hip Replacement (THR) 
1.1.1 Overview 
Total hip replacement (THR) is one of the most commonly performed elective orthopaedic operations 
with over one million being performed every year (OECD, 2016). It has been shown to reduce pain 
and improve function in patients with end-stage osteoarthritis (OA) and also to be cost-effective 
(Ferguson et al., 2018).  
Modern hip replacement, as we know it, began in the 1960s with Professor Sir John Charnley’s “low 
friction arthroplasty”. He famously stated that he did not feel a THR could last over 30 years 
(Charnley, 1961), a prediction that has subsequently proven to be too conservative. Typically, a THR 
is comprised of a femoral component or “stem”, onto which a femoral head is attached (which 
replaces the patient’s original ball) and an acetabular component or cup (that replaces the patient’s 
own socket). Many different brands and designs of both stem and cup are manufactured and marketed 
for use all over the world in combination with each other. In 2017, there were at least 822 different 
combinations of stem and cup implanted in England, Wales, Northern Ireland and the Isle of Man. 
Whilst 468 (57%) of these constructs were used fewer than five times in under 1% of patients, there 
were still 354 different constructs used more frequently.  The 10 most commonly used constructs only 
account for just over half (53%) of THRs implanted, with the remaining 46% of patients receiving an 
implant used between five and 1,941 times. It is commonly believed that there is real variation in 
survival patterns between different prostheses and implant choice remains a much debated and 
controversial subject (Wroblewski et al., 2009, Briggs, 2015, Bayliss et al., 2017, National Joint 
Registry for England, 2018b, Deere et al., 2019).  
Given time, all hip replacement components will fail for one of several reasons such as wear and 
loosening, fracture, infection or dislocation. When a THR component fails it often requires an 
operation to change it for a new prosthesis - commonly termed revision. The longevity or survival of a 





criticisms for its limitations as a crude tool (Wylde and Blom, 2011). Many statistical techniques have 
been described as appropriate for the cumulative estimation of prosthesis survival in arthroplasty, 
however the method described by Kaplan and Meier in 1958 still remains the backbone of survival 
analysis (Kaplan and Meier, 1958). Historically, reports of THR survival came from surgeon reported 
case-series published in medical journals. The advent of arthroplasty registers in the 1970s has 
subsequently provided greater numbers of THRs for inclusion in analyses and thus improved the 
precision and generalisability of survival estimates. There are currently over 20 national arthroplasty 
registers worldwide and most make use of linkage to routine and national data to provide accurate 
survival estimates.  
Several countries publish maximum acceptable prosthesis revision rates to help guide surgeons and 
patients in their choice of prosthesis - a process known as benchmarking. In the UK, the National 
Institute of Health and Care Excellence (NICE) only recommends individual THR components for use 
in people with end-stage arthritis if they have 10-year revision rates (or predicted rates) of ≤5% 
(NICE, 2014b). Patients may expect their THR to last longer than 10 years and with so many different 
prostheses (with varying revision rates) available to surgeons and patients, a guideline benchmark past 
10 years could be required, or be at least helpful. 
1.1.2 History 
Excision arthroplasty of the hip joint was described as early as the 18th century but the first recorded 
hip arthroplasty using a prosthesis is reported to have been performed in Germany by Themistocles 
Gluck in the 1890s (Gomez and Morcuende, 2005, Brand et al., 2011). His attempts at arthroplasty of 
the hip joint using ivory prostheses were all reported to fail within a few months predominantly due to 
pre-standing infection. The pioneer of THR in the UK was Sir Phillip Wiles who in 1938 performed 
the first THR in the UK at the Middlesex Hospital (Wiles, 1958). Developments in the understanding 
of biomaterials and surgical technique over the subsequent decades led to the development of the 
modern day cemented THR by Sir John Charnley in 1962. Sir John Charnley’s “low friction 
arthroplasty” may not be the first example of the use of bone cement to anchor a hip replacement but 





subsequently been based on the theories developed by Sir John, most notably the “Exeter” hip 
developed by Robin Ling and Clive Lee at the Princess Elizabeth Orthopaedic Hospital in Exeter, 
Devon. Intended to be implanted by a posterior approach and using the taper slip theory of cemented 
stem fixation, a derivative of their original design was the most commonly implanted THR component 
in the UK in 2017 (National Joint Registry for England, 2018b). 
A THR is made up of individual components (herein referred to as prostheses) that commonly include 
a femoral stem, modular femoral head and a cup that is either monobloc or a metal shell with a 
modular liner (Figure 1). The combination of a stem (with modular head) and cup (with modular 
liner) is referred to as a “construct”. Stems and cups can be fixed to bone either with 
polymethylmethacrylate cement or without, usually using press fit and subsequent bone ingrowth to 
achieve fixation. 
Figure 1 - Components of a total hip replacement (THR) demonstrating a modular liner inside a press-fit shell and a 






Desire to improve outcomes following hip replacement has led to innovation in both prostheses 
design and surgical technique. An early example of one such development was the use of the 
aforementioned press-fit prostheses that are fixed to the skeleton without the use of bone cement. The 
use of press-fit or “cementless” prostheses dates back almost as far as cemented equivalents and 
debate regarding the benefits of the two methods of fixation remains ongoing.  
One of the biggest developments of recent times in the analysis of THR success has been the shift of 
attention away from the design of prostheses towards other factors such as cost-effectiveness and the 
impact of surgeon volume on outcomes. The Getting it Right First Time (GIRFT) initiative in the UK 
started with a national review of adult elective orthopaedic services in England in 2015 (Briggs, 
2015). This report focuses on the variation in practice between units that deliver arthroplasty and 





1.1.3 Epidemiology and current practice 
There were 91,698 primary THRs recorded in the NJR in 2017 and it is estimated that over 1 million 
are performed worldwide every year (OECD, 2016, National Joint Registry for England, 2018a). The 
most common indication for THR in the UK is osteoarthritis, one of the ten most disabling diseases in 
developed countries. Worldwide estimates suggest that 10% of men and 18% of women aged over 60 
have symptomatic osteoarthritis and that 25% of those cannot adequately perform the major daily 
activities of life (WHO, 2014, National Joint Registry for England, 2018a). The aetiology of hip OA 
is multifactorial with both genetic and environmental factors influencing biological and mechanical 
components. Osteoarthritis is more common in women than in men and age is the greatest risk factor 
for development of the disease (Glyn-Jones et al., 2015). In keeping with this, 59.8% of THRs in the 
NJR to date have been performed on female patients and the overall median age of patients 
undergoing THR is 69 years (IQR 61-79) (National Joint Registry for England, 2018a). 
As previously discussed, all hip replacements will fail if in situ long enough due to the normal 
processes of wear and loosening but THRs can fail prematurely for several reasons. These commonly 
include infection, abnormal wear, loosening, dislocation, persistent pain or fracture (National Joint 
Registry for England, 2018a). When a THR fails it often requires surgical revision which is 
substantially less effective and costlier than the primary procedure (Vanhegan et al., 2012, 
Lenguerrand et al., 2016, Hunt et al., 2018). In addition to poorer outcomes further surgery exposes 
patients to the risks of another anaesthetic and surgical procedure as well as the subsequent in-patient 
hospital stay. The high numbers of hip replacements performed in the UK (91,698 in 2017) mean that 
a small percentage difference in overall revision rate may result in a large absolute change in the 
numbers of patients requiring revision surgery. A 1% reduction in overall revision rate in the THRs 
implanted in just one year could potentially result in 917 fewer patients (from that year) requiring 
revision surgery. As well as the lives of these patients this carries a significant cost to the National 
Health Service (NHS) and as such all involved in hip replacement should approach decisions that 





Surgeons and manufacturers have made many adaptations in prosthesis design to delay the inevitable 
failure of THRs thus allowing patients a revision free life. A huge range of prostheses have been, and 
currently are, available for implantation in the UK. In 2017 over 822 combinations of stem and cup 
were implanted and this doesn’t include the many different choices in bearing surface available in 
modular prostheses (National Joint Registry for England, 2018b). Individual designs of THR can be 
grouped into several “classes”. The main “classes” of hip replacement generally refer to the mode of 
fixation of the prostheses and include cemented, cementless, hybrid (cemented stem and cementless 
cup) and reverse hybrid (cementless stem and cemented cup). The distribution of use of each class of 
THR in the UK, has changed over the time the NJR has been collecting data. In 2003 the majority of 
primary THRs (56.1%) were cemented whereas in 2017 37.8% were cementless, 30.3% hybrid and 
only 28.2% cemented. Hybrid THRs appear to be increasing in popularity with an increasing 
proportion being implanted every year of data collection, whilst cemented and cementless THRs have 
been reducing in relative frequency since 2012 and 2010 respectively.  
In addition to the method of component fixation the other options available to surgeon and patient 
include the size of the femoral head and the material of the articulating (bearing) surface. It has long 
been suggested that larger head sizes reduce the risk and subsequently the incidence of dislocation in 
both primary and revision THR (Eftekhar, 1976, Carlsson and Gentz, 1977, Etienne et al., 1978, 
Fackler and Poss, 1980, Ali Khan et al., 1981, Ekelund et al., 1992, Turner, 1994, Berry, 2001, Singh 
and Bhalodiya, 2013, Kim et al., 2017) and this hypothesis has been supported by more contemporary 
evidence from both randomised trials and analysis of registry data (Jameson et al., 2011, Garbuz et al., 
2012, Howie et al., 2012, Howie, 2018). The use of larger heads may however come with an increased 
risk of wear and subsequent loosening. To combat this, developments have been made in bearing 
surfaces from the originally used metal on polyethylene bearing. The use of harder bearing surfaces 
such as metal or ceramic reduce wear but are more expensive and can be associated with other 
complications (Smith et al., 2012a, Smith et al., 2012b). The reduced wear profile of ceramic bearings 





1.1.4 Cost effectiveness 
Total hip replacement carries with it financial costs associated with both the primary care episode as 
well as the those of any subsequent follow-up care or revision surgery. The primary care episode costs 
typically include purchasing of prostheses, inpatient stay, and operating theatre time. In a study by 
Fordham et al, The Exeter Primary Outcomes Study group estimated the cost of a primary episode of 
care in 2012 to be approximately £5,000 for patients receiving an “Exeter” total hip replacement 
prosthesis (Fordham et al., 2012). They calculated and compared the cost per Quality-adjusted Life 
Year (QALY) against a hypothetical “no surgery” group.  Fordham et al estimated that “85% of cases 
had a cost per QALY of £20,000 or less with 70% of these having a cost per QALY of under 
£10,000”. In general, NICE recommends that interventions with an Incremental Cost Effectiveness 
Ratio (ICER) of less than £20,000 per QALY gained are considered cost effective (NICE, 2014a). 
This suggests that THR is a cost-effective procedure under the NICE standards, a conclusion that has 
also been confirmed by several other studies (Marinelli et al., 2008, Di Tanna et al., 2011, Daigle et 
al., 2012, Pennington et al., 2013, Clarke et al., 2015, Pulikottil-Jacob et al., 2015). 
As discussed above, there are many different classes of THR, both in terms of method of fixation, 
bearing surface and head size. In 2012, from an analysis of NJR data, Griffiths et al suggested there 
were potential cost savings to be made by the NHS with the exclusive use of cemented prostheses 
(Griffiths et al., 2012). This article does not however consider the variation in survival profiles 
between patients of differing age and gender and any potential interaction between femoral and 
acetabular prostheses. Fawsitt and colleagues, in their previously mentioned article used a combined 
cost-effectiveness analysis of both the NJR and the Swedish Hip Arthroplasty Register (SHAR) to 
look at different prostheses designs, head sizes and bearing surfaces in patients of differing ages 
(Fawsitt et al., 2018). They suggest that in patients (both men and women) over the age of 65 
cemented, small head (<36mm), metal on polyethylene THRs were the most cost-effective whereas in 






1.2 How do we measure success following THR? 
 
“The ultimate measure by which to judge the quality of a medical effort is whether it helps patients 
(and their families), as they see it. Anything done in health care that does not help a patient or family 
is, by definition, waste, whether or not the professions and their associations traditionally hallow 
it.”  
(Berwick, 1997) 
Traditionally, there are two main criteria upon which the success of a THR may be assessed: the 
satisfaction of the patient who has received the THR and how long the prostheses remain in situ 
without surgical revision (survival). Revision of a prosthesis is an attractive endpoint to researchers as 
it is a well-defined binary measure. It does however have limitations. This concept was neatly 
discussed by Wylde in an editorial for the JBJS(Br) in 2011 and I will attempt to summarise and 
update the salient points here (Wylde and Blom, 2011). 
1.2.1 Patient Reported Outcomes 
The principle aims of THR are to reduce pain and restore activity thus improving physical and 
psychosocial wellbeing. It is generally accepted that THR achieves this in approximately 90% of 
cases (Nikolajsen et al., 2006, Learmonth et al., 2007, Ferguson et al., 2018). The process of assessing 
these factors is not however as simple as it may appear at first glance.  
Traditionally pain and activity were assessed by clinicians using clinic-based scoring systems but 
more recently there has been a move towards analysis of Patient Reported Outcomes (PROs). These 
are collected using Patient Reported Outcome Measures (PROMs) designed to be completed by 
patients themselves. The use of PROMs aims to reduce potential bias by clinicians or researchers, but 
the measures themselves must be “validated” prior to use to prove reliability and reproducibility. 
Routine national collection of PROMs following arthroplasty has been in place in the UK since 2009. 
In the case of THR this consists of three scoring systems: Oxford Hip Score (OHS), EQ5-D and EQ-





completed, 12-point questionnaire regarding the activities of daily living. It is validated specifically to 
assess pain and function following THR although it has also been used in other settings. The other 
two PROMs are more general quality of life indicators. Further information regarding the national 
PROMs programme is found in the King’s Fund publication “Getting the most out of PROMs” 
(Devlin and Appleby, 2010). The perceived success of a joint replacement varies according to 
whether survival, a patient reported outcome or a combination of the two is analysed. A study by 
Bullens and colleagues of patients who had undergone total knee replacement suggested a rate of 
success of 96.7% if purely defined by survival (Bullens et al., 2001).  In the same article, if success is 
instead defined as survival plus satisfaction this dropped to 93.3% and when defined as survival, 
satisfaction and pain relief, the figure dropped further to 68.8%. Similar results have also been 
observed in THR (Britton et al., 1997). There are however challenges to research based on the 
analysis of PROMs, most notably “floor” and “ceiling” effects. These effects are phenomena 
frequently observed in PROMs, since any scoring system must have a maximum and a minimum 
score and patients will often report these extreme scores. How to deal with these “floor” and “ceiling” 
scores is much debated and remains a weakness in the analysis of PROMs. 
Patient Reported Outcomes need not be limited to the use of PROMs and this is reflected in a recent 
increase in the use of more subjective, qualitative research to look at outcomes following THR 
(McHugh and Luker, 2012). Historically, arthroplasty research has focused on quantitative work. 
However qualitative methods are increasingly important, particularly regarding hypothesis generation 
and formation of more patient centred assessments of success. 
1.2.2 Survival 
The survival of a THR is generally considered to be the amount of time it remains in situ prior to 
revision surgery. It is a crude but relatively well-defined measure of the success of a THR. Each THR 
can only be in one of two groups: in situ or revised. Despite this, the use of survival as a measure of 
success has its limitations. Using revision surgery as a proxy of failure does not of course consider 
THRs that have failed (resulting in pain or poor mobility) in patients who have declined, not been 





Survival analyses can be performed for a range of endpoints as defined by the authors of individual 
studies. Authors may create subgroups of patients, in which an individual part of a construct, such as 
the femoral stem, has been revised. Whilst this may provide interesting information about that 
prosthesis it assumes that failure of one component is independent of all other parts of the construct. It 
also does not consider the fact that as far as a patient is concerned the need for any further operation 
may be regarded a failure, regardless of which component was revised.  
Revision is a relatively rare outcome following THR (National Joint Registry for England, 2018a). 
Therefore, as Wylde states, large sample sizes and long follow-up periods are required to detect 
significant differences in survival rates between prostheses. As such, the use of survival as a primary 
outcome should be limited to studies with large numbers of THRs, typically only found in registry-
based studies. 
1.2.3 Combinations of outcomes 
In his 2010 article “What is value in health care?” Michael Porter discusses a three level model of 
outcome selection (Porter, 2010). What he terms “Level 1 outcomes” include survival, mortality and 
the functional and pain level achieved following intervention, “Level 2 outcomes” which are 
measures related to the recovery process such as time to treatment and complications, with “Level 3 
outcomes” related to the long-term or sustained consequences of treatment. He states that “when 
assessing the overall management of a disease or treatment, measurement efforts should begin with at 
least one outcome in each tier”. Applying this model to an arthroplasty setting we see that our two 
traditional methods of assessing the success of arthroplasty fit into tier 1 (PROMs) and tier 3 (time to 
revision). This suggests that any overall assessment of the success of THR should use both of these 
measures rather than simply selecting one, a point also made by Wylde (Wylde and Blom, 2011). 
1.3 Commonly used survival analysis techniques 
Survival analysis is the process of analysing data with time to an event (in this case failure or 
removal/revision of a prosthesis) as the outcome. Patients or participants may have different lengths 





the analysis stage (Murray et al., 1993). The ability to estimate prostheses survival is key in providing 
patients with accurate information about prognosis as well as enabling surgeons to make informed 
choices regarding the best stem and cup combinations. One major challenge in the estimation of 
prosthesis survival is the fact that patients may die for unrelated reasons with a well-functioning THR 
in situ. This is to be expected when the majority of THRs are implanted in those aged over 65 and the 
lifetime risk of revision of a THR in patients over 70 years old is only 5% (Bayliss et al., 2017, 
National Joint Registry for England, 2018a). 
A number of statistical techniques have been used to estimate arthroplasty survival but probably the 
most commonly used was described by Kaplan and Meier in 1958 (Kaplan and Meier, 1958, 
Armitage, 1971, Dobbs, 1980). Their seminal paper “Nonparametric Estimation from Incomplete 
Observations” describes the statistical function for estimating the life of a vacuum tube. The study 
setting was one where an experiment may be brought to a premature end because vacuum tubes may 
break for unrelated reasons or test facilities may be needed for other experiments.  This setting is in 
many ways analogous to the analysis of arthroplasty patients - a patient may die with a well-
functioning arthroplasty (akin to breakage of the vacuum tube) or the patient may be lost to follow-up 
(premature closure of the laboratory in a functioning vacuum tube). One key assumption in the use of 
the Kaplan-Meier method in arthroplasty is that undergoing an arthroplasty itself must not increase 
the chances of dying prematurely. Recent work by Cnudde and colleagues suggests that this is not the 
case. In fact, they suggest the converse may be true in that undergoing THR may improve survival 
compared to the general population (Cnudde et al., 2018). The methods used to calculate confidence 
intervals to support point estimates has also been the subject of much debate, notably that in 
prostheses with high survival, confidence intervals may exceed 100% (Greenwood, 1926, Rothman, 
1978, Murray et al., 1993, Kalbfleisch and Prentice, 2002). This debate is however, beyond the scope 
of this thesis.  
In the last few years there has been a trend towards criticism of traditional Kaplan-Meier methods and 
therefore an increased use of a competing risks analysis method (Biau et al., 2007, Keurentjes et al., 





2017). In a recent paper, we discuss at length the fact that the two methods provide estimates of 
different things and therefore should not be compared (Sayers et al., 2018). A traditional Kaplan-
Meier method estimates net survival (the probability of a prosthesis lasting a particular length of time 
in an immortal patient) in contrast to the competing risks model which estimates crude survival (how 
likely a prosthesis is to last a particular length of time in a patient who may die for another reason). 
Neither of these estimates provides a relative “over-estimate” (as is suggested in recent literature) 
because they simply estimate different things (Lacny et al., 2015, Porcher, 2015, Lampropoulou-
Adamidou et al., 2017). If a patient wishes to know what the chances are of their prosthesis lasting a 
certain length of time, a crude estimate is helpful whereas if a healthcare commissioner wants to pick 
the longest lasting prosthesis then a net estimate is more informative. 
As mentioned previously, one key element of survival analysis is the end-point or chosen outcome i.e. 
the event that causes the patient to be removed from analysis. This is typically known as the failure 
event. Many different end-points can be, and are, used when discussing THRs. Analysts may look at 
revision surgery performed for any reason, for clinical failure or for radiographic failure. Some 
analyses selectively report certain modes of failure (such as aseptic loosening) or only consider failure 
of one component to be of interest (such as failure of the femoral stem). The choice of end-point is 
key to any research and it is vital that authors choose one that is relevant to their chosen research 
question. 
The methods discussed so far are the most commonly used. However, they have their limitations 
when it comes to comparisons of outcomes in the presence of co-variates or confounders. Kaplan-
Meier curves may be presented stratified for a co-variate (such as gender). However adjusted analyses 
are not possible with this technique. To produce an adjusted analysis of time to event data regression 
techniques, such as the Cox proportional hazards model or a Fine and Gray model, may be employed 
(Cox, 1972, Fine and Gray, 1999). These techniques also have limitations, most notably that they are 
only semi-parametric (in that they do not produce a baseline hazard) and that outputs are given as a 
hazard ratio (HR) which may be difficult to interpret. Most importantly, in the analysis of arthroplasty 





remain proportional between the two groups. An arthroplasty example of a situation where this 
assumption is violated is when comparing revision for fracture between cementless and cemented 
THR prostheses. Cementless prostheses are more likely to experience early fractures than cemented 
equivalents (which typically experience fracture as a later complication), thus meaning the 
proportional hazards assumption will almost be immediately be violated (Abdel et al., 2016). More 
recently described techniques, such as Flexible Parametric Survival Analysis, developed by Royston 
and Parmar, allow the modelling of time dependent effects as well as the estimation of a baseline 
hazard. These models also serve to be of great use in predictive or prognostic modelling (Royston and 
Parmar, 2002). Prognostic survival models can give an estimate of prosthesis survival at different time 
points given certain patient characteristics such as age or sex.   
1.4 Sources of survival data in arthroplasty 
When making informed decisions regarding choices of prostheses surgeons, patients or 
commissioners must evaluate existing evidence. As discussed above, survival is only one metric of 
the success of a THR, although it is an important and commonly used one. Information on the survival 
of THRs principally comes from two sources, individually published case-series from centres holding 
long-term follow-up data on their patients and larger (often national) arthroplasty registers. 
1.4.1 Case-series 
Medical journals are one of the first methods used by scientists and medical professionals to share the 
results of new techniques or treatment. As such, journal articles were the original source of data 
regarding the results of arthroplasty and there is clear evidence of their use in prosthesis selection in 
arthroplasty (Murray et al., 1995). A surgeon or team of surgeons may keep a prospective database of 
the recipients of a prosthesis or construct and then publish their results, either in terms of clinical or 
survival outcomes. There are many examples of this in the literature of this dating from the 1950s to 
the present day.  
There are several potential sources of bias associated with the use of a single centre case-series. 





geographic area and may represent a specific socio-economic demographic. Selection bias may also 
be present as surgeons may only offer THRs to certain patients or groups of patients. Reports may be 
subject to publication bias - a surgeon may choose not to submit non-favourable results for 
publication and editors may not publish all submitted series. By their very nature, single centre case-
series will consist of relatively low patient numbers therefore being more susceptible to loss to follow-
up and censoring for death, leaving fewer patients at risk at reporting times. There are however some 
strengths to results reported in smaller single centre series. With a smaller, more intimate cohort 
authors can be expected to know more detail regarding outcomes compared to a database relying on 
linkage. This may include PROMs or clinical failures in patients not suitable for revision surgery. 
1.4.2 Arthroplasty registries  
The first national arthroplasty registry was the Swedish Knee Arthroplasty Registry (SKAR) formed 
in 1975. Since then, many more regional and national arthroplasty registers have formed. At the time 
of writing, the International Society of Arthroplasty Registries (ISAR) has 38 full registry members.  
The National Joint Registry for England and Wales (NJR) was formed in 2002, partly in response to 
the 3M Capital hip controversy and subsequent recommendations from the Royal College of Surgeons 
of England (Muirhead-Allwood, 1998, The Royal College of Surgeons of England, 2001). The NJR 
started collecting data on hip and knee replacements in April 2003 but has now expanded to include 
ankle (April 2010), elbow (April 2012) and shoulder replacements (April 2012). Northern Ireland 
joined in February 2013 and the Isle of Man in July 2015. The NJR serves several goals, including 
acting as an early warning system for prostheses and to highlight hospitals and surgeons falling below 
expected performance limits (NJR Centre). This role of “potential outlier identification” is unique to 
the NJR and not currently adopted by any of the other national registries. 
The main benefit of a national arthroplasty register in the reporting of prostheses survival lies in the 
large numbers of joint replacements collected offering greater generalisability of results. On 31 March 
2018 the NJR held records on approximately 2.5 million joint replacements including 992,090 THRs 
(National Joint Registry for England, 2018a). The use of data linkage for both identification of 





in the use of registry data. The data is only as accurate as that input to the system and as such, failures 
of data entry can be passed on to become errors in results down the line. There has been criticism of 
NJR data in the literature, most notably to do with the accuracy of linkage in identifying revision 
procedures (Konan and Haddad, 2013, Sabah et al., 2015, Sabah et al., 2016). It must be remembered 
that the NJR relies on a proxy measure (completion of a form) in the identification of revision surgery 
and is therefore susceptible to under-reporting. The 14th NJR annual report (2017) describes the 
results of the NJR data quality audit, suggesting that approximately 97% of primary THRs and 95% of 
revision THRs are recorded in the NJR (National Joint Registry for England, 2017a). Missing data is 
an important limitation and potential source of bias within any study and this remains true in the NJR. 
Data for a specific patient may be missing either in part (individual fields or variables) or completely. 
The impact of completely missing records will vary according to whether the primary operation was 
recorded and what would have happened to arthroplasties that were not originally reported to the NJR. 
Patient records that are completely missing may have different impacts on results depending on how 
that data is missing. Data may be missing either “not at random”, “at random” or “completely at 
random”. Records missing “not at random” i.e. missingness of a record is related to its values, are a 
source of selection bias as these records may be associated with higher failure rates and therefore lead 
to underestimation of revision burden. Records missing “at random” or “completely at random” are 
typically referred to as “ignorable” (Enders, 2010), this is because the missingness of the data is not 
related to any values of the missing record; for example, data is not missing because of a high or low 
risk of revision. These records are less likely to make an impact on any associations observed from 
the overall NJR and therefore be a source of bias. An attempt to limit the problem of missing data was 
made in April 2011 when recording of data in the NJR became mandatory (HQIP), however as the 
results of the NJR audit has shown, this has not completely resolved the issue. 
Whilst the presence of arthroplasty registers in many countries potentially increases the data available 
for analysis and comparison it is important to remember that systematic differences between registries 
impact on results. There may be cultural differences between countries regarding thresholds to 





revision surgery in the NJR is “the addition, removal or modification of any part of the construct”. It 
is therefore possible for a patient to undergo surgery for a peri-prosthetic fracture and for it not to be 
highlighted in the NJR as a revision. In addition to this, it may also encourage surgeons who are often 
concerned about becoming a potential outlier in the NJR to fix a peri-prosthetic fracture instead of 
revising the prosthesis. 
The other major limitation of registry data, particularly the NJR, is that it is limited by the length of its 
data collection. At the time of writing the NJR has 14.2 years maximum follow-up so survival 
estimates must either be shorter than this or predictive in nature. 
1.5 The Exeter V40 femoral stem 
One of the implants in the NJR with both the highest frequency of use and the longest follow-up is the 
Exeter V40 femoral stem (Stryker Orthopaedics, Mahwah, New Jersey). The original Exeter stem was 
first used in November 1970 and remained on the market until 1976 (Ling et al., 2009). It was 
developed by Robin Ling and Clive Lee at the Princess Elizabeth Orthopaedic Hospital, Exeter, 
Devon in conjunction with the University of Exeter. Having observed less than satisfactory results 
using the McKee-Farrar hip replacement between 1965 and 1969 a decision was made to design a 
new prosthesis that would be implanted using acrylic bone cement via the posterior rather than the 
lateral approach (with trochanteric osteotomy) that, at the time, was being used for the Charnley low-
friction arthroplasty. Based around what later became known as the taper-slip principle (Fowler et al., 
1988, Shen, 1998) the collarless, double taper design aimed to improve extrusion of cement into the 
endosteal surface of the femur. The original stem was manufactured with a “polished” finish due to 
British manufacturing standards associated with the metal used (stainless steel, EN58J); although this 
was a chance decision it has subsequently been shown to be one of the keys to success of the design 
(The Exeter hip : 40 years of innovation in total hip arthroplasty., 2010). The long term results of the 
first 433 THRs performed using this original Exeter stem were published in 2009 and reported 93.5% 
survival (for aseptic loosening) after 26 years (Ling et al., 2009). Since the original stem there have 
been several changes and modifications made to the Exeter stem that haven’t all proven to be 





subsequent loosening of the stem and this was subsequently attributed to the change from a polished 
to a matte finish (Howie et al., 1998). This increase in early failures highlighted the importance of 
outcome monitoring, a principle that was key to Ling and Lee and continues at the PEOC to this day. 
The surface finish of the stem was changed back to highly polished in 1986 before further 
modification in 1988 to allow the use of modular heads. Consistent survival results with the 1988 
version (the Exeter Universal stem) have been reported both by surgeons in Exeter and elsewhere 
(Hook et al., 2006, Lewthwaite et al., 2008, Carrington et al., 2009, Young et al., 2009, Petheram et 
al., 2016). In 2016, Petheram et al reported the survival (for aseptic loosening) of the first 236 Exeter 
Universal stems of 99% (95% CI 97.0, 100) after 22.8 years. The Exeter Universal stem remained 
unchanged until 2000 when adaptations were made to the trunnion to accommodate the use of ceramic 
heads; this most recent version is known as the Exeter V40 femoral stem. The 13.5 year results of the 
Exeter V40 femoral stem were reported in 2018 (with an end-point of survival for all-cause revision 
of any part of the construct) of 91.2% (95% CI 88.3, 94.1) which the authors described as 
“comparable to that of the Exeter Universal stem” (Westerman et al., 2018). The maintenance of a 
detailed and thorough database of all hip replacements implanted in PEOC has allowed the Exeter hip 
research team to monitor the performance of implants both for safety reasons as well as reporting 
results to the rest of the orthopaedic community, well before the formation of the NJR. 
 
1.6 Existing benchmarks for survival of THRs 
benchmark, v. 
transitive. “To evaluate or check (something) by comparison with an established standard; to 
measure against a comparable or equivalent point of reference, esp. in order to assess performance 
or set performance standards.”  
(Dictionary) 
Benchmarking in arthroplasty survival is the process by which the survival of a prosthesis (or 





suggest which prostheses are recommended for implantation. The standard often refers to the 
proportion of prostheses that are still in-situ or unrevised at a specific time point, for example 10 years 
after surgery. The process of benchmarking compares individual prostheses to a pre-defined standard 
rather than to the performance of other contemporary prostheses. The benefit of benchmarking against 
a defined standard is the simplicity of understanding for patients, surgeons, commissioners and 
manufacturers. This system is, however, highly reliant on the careful interpretation of presented 
evidence against the defined standard. The main weakness of benchmarking against a defined 
standard rather than against other contemporary prostheses is the fact that whilst two prostheses may 
both reach the required benchmark one may demonstrate inferior performance to the other, as recently 
demonstrated by Deere and colleagues (Deere et al., 2019). In their 2017 simulation study, focused on 
medical devices, Sayers et al demonstrated that small non-inferiority margins require significantly 
more individuals to be at risk (approximately 1600) compared with current benchmarking standards 
(Sayers et al., 2017). Whilst a system of direct comparison (as described by Sayers) may produce 
greater accuracy, it would be much harder to implement and may exclude many prostheses from 
analysis as there are many prostheses available and thus insufficient numbers at risk at greater follow-
up periods. 
1.6.1 United Kingdom 
The National Institute for Health and Care Excellence is a UK body providing “national guidance and 
advice to improve health and social care” (National Institute for Health and Care Excellence). This 
aim is principally achieved by the publication of guidance documents in one of 13 areas including: 
clinical guidelines, diagnostics guidance and medical technologies guidance. The document advising 
on the use of THR prostheses is Technology Appraisal Guidance 304 (TA304) with the most recent 
update published in 2014 (NICE, 2014b). Current guidance recommends individual THR components, 
for use in people with end-stage arthritis, if they have 10-year revision rates (or predicted rates) of 
≤5%. Notably, the guidance refers specifically to individual components rather than a construct. The 
benchmark figure of a 5% revision rate at 10 years post-surgery was based largely on a study of NJR 





of a larger report produced by Warwick University to provide evidence for the 2014 update to TA304 
(Clarke et al., 2013). A critical appraisal of the article by Kandala et al is found later in this thesis. 
Patients, clinicians and commissioners of healthcare are guided in their choice of prostheses by the 
Orthopaedic Data Evaluation Panel (ODEP). Founded in 2002 by the National Health Purchasing and 
Supply Agency (PASA), ODEP was set up to help implement NICE guidance on primary hip 
prostheses but has subsequently started providing information on hip resurfacing (2004), knee 
replacements (2014) and shoulder replacements (2017). Information (in the form of research articles 
or registry output) is submitted to ODEP by manufacturers of prostheses before evaluation by a “panel 
of experts comprised mainly of leading UK surgeons but also non-clinical experts with deep 
experience of the orthopaedic industry” (Orthopaedic Data Evaluation Panel). After appraisal of data 
each prosthesis is awarded a rating referring to the number of years for which performance was 
evaluated (at pre-defined time points) and the quality of the evidence provided. A rating of 10A* 
signifies the panel believes a prosthesis meets the criteria specified by TA304 (strong evidence of an 
all-cause revision rate (1-KM) of <5% after 10 years). The criteria for the award of each ODEP rating 
in hip replacement is seen in Appendix 1. In 2018, ODEP extended their benchmarking criteria to 
include a 13A* rating, denoting a revision rate under 6.5% at 13 years. At present, ODEP do not 
publish revision rates for hip replacement constructs but only the constituent parts and this is in 
keeping with the guidance issued in TA304. 
1.6.2 International 
Since 2015 the Dutch Orthopaedic Association (Nederlandse Orthopaedische Vereniging (NOV)) has 
used a benchmarking system based broadly on NICE guidance TA304. This was organised through a 
Committee for Orthopaedic Implants Classification (COIC). In 2018 however, the NOV elected to 
fully adopt the ODEP system as used in the UK. The NOV recommends using a prosthesis with an 
ODEP “A” or “A*” rating at 5, 7 or 10 years denoting a revision rate of under 10% at each time point 
(NOV website). 
The Australian Orthopaedic Association (AOA) awards a Superior Clinical Performance (SCP) suffix 





prostheses meeting these criteria is associated with a financial uplift in tariff for performing the joint 
replacement operation. Like ODEP, the main requirement for achieving the SCP standard is an 
observed revision rate of less than 5% at ten years. The evidence base and adopted methodology for 
calculating this figure is, however, different to that used by ODEP.  
1.7 Critical appraisal of existing literature 
To give an idea of the types of article previously published regarding survival of hip arthroplasties, a 
typical example of a published case-series and an analysis of registry data have been selected for 
critical appraisal.  
1.7.1 Example of a long-term case-series 
As discussed above, published case-series have long provided information on the survival of THRs 
and THR components. This critical appraisal of a contemporary article investigating the survival of a 
commonly used prosthesis as an example of some of the strengths and weaknesses of case-series in 
reporting survival data. A copy of the article can be found at Appendix 2 - Jacquot L, Bonnin MP, 
Machenaud A, Chouteau J, Saffarini M, Vidalain J-P. Clinical and radiographic outcomes at 25 to 30 
years of a hip stem fully coated with hydroxylapatite. The Journal of Arthroplasty 2017. (Jacquot et 
al., 2017) 
1.7.1.1 Title and abstract 
The title of this article is clear, indicating that the authors intend to report both clinical and 
radiographic findings of one stem at 25 to 30 years of follow-up. The study design (case-series) is not 
specifically stated in the title but is implied. The abstract is clear and informative, all important results 
are stated, and the conclusions drawn are relevant and in keeping with the body of the article. 
1.7.1.2 Introduction 
The introduction provides a clear rationale for the study, namely, to report survival and radiographic 
findings of this femoral stem at follow-up times greater than 25 years. The authors clearly state the 






The study design is described in the in the first sentence of the methods and it becomes clear that this 
is a case-series. The setting of the study, dates of recruitment and inclusion criteria are sufficiently 
detailed. There has been no attempt to justify the sample size although this is not uncommon for case-
series. The authors adequately describe the methods used for patient follow-up in all potential 
scenarios and these appear robust. The primary exposure is clear in that the study includes any THR 
implanted at this unit using the “Corail” stem. The brands of cup used are not stated and this could be 
an important factor given the potential interaction between stem and cup. The outcomes chosen by the 
authors are a strength of this study in that they report most survival end-points of interest.  
The statistical methods are stated clearly and in the survival analyses include a sensitivity analysis 
with two commonly used methods. The authors interpretation of the difference between Kaplan-Meier 
(KM) and Cumulative Incidence Function (CIF) is not in keeping with mine (see page 10 of this 
thesis) (Sayers et al., 2018) although they have provided justification for their decision. The authors 
clearly state the number of patients lost to follow-up but do not discuss how these patients were 
handled – it is not shown whether they were they excluded from analyses or was a “worst-case 
scenario” taken? The outcome measure for clinical assessment is stated clearly (Harris Hip Score) and 
the methods used for radiographic evaluation are clear. Justification for the choice of outcome 
measures is not provided. An attempt has been made to avoid bias in the interpretation of radiographs 
i.e. two observers, although further detail is needed as to how this was performed. Were all 
radiographs examined by both reviewers and if so, what was the agreement between them? 
1.7.1.4 Results 
A flow chart of patients is provided detailing how many patients were in each outcome group and how 
many were lost to follow-up or censored. The patient demographics are discussed in the methods 
section including indication, sex, age and BMI. This encompasses most of the widely accepted co-
variates that may influence survival of an arthroplasty enabling the reader to assess the 
generalisability of the study. The crude survival results presented in this study are provided with an 





provided with a mean, median and a range. Helpfully, numbers of joints “at risk” are provided within 
the figures. The results of clinical and radiographic outcomes are described, and the authors correctly 
note that these were subject to a high loss to follow-up. They correctly state this is secondary to the 
age of patients in this study and that this reduces the power. 
Two designs of femoral stem (collared and collarless) were included in this study and although sub-
group analysis was performed for the primary end-point these analyses are unadjusted and 
underpowered and conclusions for this subgroup analysis should be interpreted with caution. 
1.7.1.5 Discussion 
The discussion begins by restating the study objectives and providing a brief summary of the key 
results. The authors compare their results to other similar articles (with a very helpful table of results) 
and quite rightly state that these comparisons must be interpreted cautiously because of 
methodological differences. An interpretation of the subgroup analysis is provided but the authors do 
not adequately express how these results should be interpreted with caution. They state “none of these 
differences were statistically significant, possibly due to insufficient sample size” rather than correctly 
reporting that the study was not designed or powered for this kind of sub-group analysis. The authors 
do not make it clear at what time-point their stated survival estimates are calculated. From comparison 
to the figures it appears they report 30-year survival at which point very few hips are “at risk”. A 
more modest interpretation at an earlier time point with more hips “at risk” would be more useful to 
the reader (Lettin et al., 1991, Murray et al., 1993). 
The authors do state limitations of the study and quite rightly cite the high loss to follow-up as a major 
limitation. No mention of potential bias is given within the limitations section. Little effort is made to 
discuss the generalisability of results.  The fact the study reports the results of a single surgeon is 
stated as a strength but in fact could reduce the generalisability. The main limitation of the study is the 





1.7.1.6 Overall summary 
In summary, this article clearly sets out its objectives and subsequently achieves these. It is flawed by 
the nature of the study design itself and as a result the results may not be generalisable and potentially 
display inaccuracies, particularly regarding the low numbers included and high loss to follow-up. The 
author’s interpretation of the difference between KM and CIF is controversial and once the results are 
stated interpretation of this difference should be left to the reader. The sub-group analysis (of collared 
and collarless stems) is unhelpful as it is not one of the aims of the study and as such is underpowered 
and should be interpreted with great caution. Overall, this is a typical example of a case-series in 
arthroplasty with potentially more robust analyses and methods than many others but still susceptible 
to the same limitations. 
1.7.2 Reports of registry data 
Another source of information regarding THR survival is arthroplasty registry data and published 
analyses of these. The UK survival benchmark for THRs, provided in NICE guidance document 
TA304, of  a single component having an observed or predicted revision rate of <5% at 10 years is 
based in part on an analysis of NJR data performed by Kandala and colleagues (NICE, 2014b, 
Kandala et al., 2015). This critical appraisal highlights some of the strengths and weaknesses of 
analyses based on registry data. A copy of the article can be found at Appendix 3 - Kandala N-B, 
Connock M, Pulikottil-Jacob R, and colleagues Setting benchmark revision rates for total hip 
replacement: analysis of registry evidence. BMJ 2015; 350: h756 (Kandala et al., 2015) 
1.7.2.1 Title and abstract 
The title of the manuscript is very clear. The authors have made it clear that the aim of the paper is to 
analyse registry data to set a benchmark revision rate for THR. Further information detailing which 
registry had been analysed (NJR) and the time point for the benchmark (10 years) would have 
provided further detail and may be helpful to the reader. The information missing from the title is 
subsequently provided in the first paragraph of the abstract. Further to this, the abstract is an 






The introduction clearly explains the scientific background and rationale for the study. It describes the 
source of data for this study (NJR) but despite stating that registries in general “achieve almost total 
coverage”. No attempt is made to quantify the coverage of the data source used for the ensuing 
analyses. The NJR is described in general but further detail on how patients are recruited, and 
revisions identified (completion and submission of NJR forms) would be helpful. The final sentence 
of the introduction clearly states the objective of the study, including a description of why the work 
was done and how it may be used in a wider setting. 
1.7.2.3 Methods 
The methods again state the source of information, setting and dates of recruitment. The authors 
should state that submission of data to the NJR is mandatory for all units performing THR in England 
and Wales but despite this the NJR does not provide complete coverage. Between 2003 and 2008 
patient consent and data linkage were not 100% and there has been no attempt to describe this 
(National Joint Registry for England, 2018a). I recognise this article predates the NJR data quality 
audit but a general description of estimated coverage would be helpful. One of the strengths of a 
national registry is the use of data linkage to identify patients who have died and are subsequently 
censored and a brief description of this process would add clarity for the reader rather than assuming 
knowledge. 
The exposures (classes of hip replacement) are clearly defined in the methods section along with how 
these exposures were chosen. The authors do not however, clearly define all variables within the 
methods section, as an example: what constitutes a revision changes between registries and is a very 
important component of this research.  
The statistical methods are described clearly, and a range of different techniques was used by means 
of a sensitivity analysis. The range of techniques used is sensible and cover most of the methods used 
in the analysis of registry data. The authors give no information regarding missing data and how this 
was managed. The authors helpfully state that age and sex “influence performance of revision” 





would be even better if a reference were provided for how these potential confounders were identified 
and how they influence survival. Ten-year survival estimates were the focus of this article, but it is not 
made very clear that these estimates were based on nine-year data. Whilst this may not be a statistical 
weakness it should be made clearer to the reader.  
1.7.2.4 Results 
The authors state that 386,556 “usable” records were included in this study. It would be helpful to 
state how many records were classified as un-usable and clearly define why these records were 
discarded. The authors a priori classified different types of hip replacement which encompassed 62% 
of usable patient records, which is entirely reasonable. It would however have been useful to see the 
make-up of the other 38% of cases as the types of hip replacement may change in the future. 
Appendix A and B give very clear detail regarding the demographics of included patients and this 
includes an assessment of co-morbidity (American Society of Anesthesiology (ASA) score) as well as 
the potential confounders. The follow-up time is also summarised nicely in Appendix B. As 
previously discussed, the authors do not provide any detail on missing data, even if no data is missing 
this should be stated. 
The summary of results is both clear and comprehensive. Crude estimates and adjusted results are 
always given with confidence intervals. The authors do not however provide the numbers of outcome 
events (revisions) or numbers of patients censored. Typically, in survival analysis this is provided in 
the form of an “at risk” table. Whilst the overall number of patients in this study are large after 
stratification by sex and class of THR, the smallest group of patients is only 4,977. An “at risk” table 
would give information on how many of these patients were followed up to each time point and give a 
further guide to the accuracy of estimates. 
1.7.2.5 Discussion 
The discussion is very well structured with key results summarised early, as one would expect of an 
article in the British Medical Journal. The authors discuss the limitations in the use of NJR data in 
assessment of THR success.  The limitations they describe are both relevant and important. They do 





potential bias inherent to their results. Comparison of different types of THR are always susceptible to 
selection bias, in that surgeons choose to use certain prostheses in certain types of patients. Whilst the 
authors refer to this earlier in the paper this should be also discussed in the limitations section. The 
authors compare the results of this study to previous evidence and a degree of consistency is observed, 
adding credence to the results. An assessment of the generalisability of the results is made in the 
discussion and this follows logical principles. Overall the interpretation of the results is sensible and 
does not overstep the scope of the work conducted. 
1.7.2.6 Overall summary 
In summary, this is a clear article with robust statistical methods and large patient numbers. The 
authors set out to provide an evidence-based benchmark for 10-year survival of a THR and the 
achieved this aim. There are some minor omissions in reporting as discussed above but most of these 
would simply help a wider audience understand the article rather than being critical omissions.  
1.8 Context of the presented research 
Osteoarthritis of the hip is a common condition and the mainstay of end-stage treatment at present is 
THR. Despite the well documented success of THR there are still life changing complications that 
may arise, such as the need for revision surgery. Revision surgery is costly both to the patient and the 
health service in terms of both clinical outcome and money. There were at least 822 different stem 
and cup combinations (constructs) used in 2017 alone and it is widely accepted that there is 
considerable variation in the survival of these constructs. Survival estimates from national registry 
data potentially offer better generalisability of results than case-series, but these are limited by the 
availability of data. 
A benchmark for THR survival exists in the UK at ten years and this is largely based on an analysis of 
nine years of NJR data published in 2015. Longer term benchmarks based on individual constructs are 
harder to provide due to the length of follow-up provided by registries as well as the large variation in 





successful prosthesis could provide patients, surgeons and healthcare commissioners better 
information on the survival they can and should expect from their THRs. 
1.9 Aim and objectives 
1.9.1 Aim 
This thesis aims to predict the long-term (greater than 15-year) survival of Total Hip Replacements 
(THRs) implanted in England and Wales, Northern Ireland and the Isle of Man using the Princess 
Elizabeth Orthopaedic Centre (PEOC), Exeter local database and the National Joint Registry of 
England, Wales, Northern Ireland and the Isle of Man. 
1.9.2 Objectives 
• To provide a pooled estimate of the long-term survival of THRs based upon existing literature 
using evidence synthesis techniques. 
• To compare the survival of THRs implanted at the Princess Elizabeth Orthopaedic Centre 
(PEOC), Exeter to that of THRs implanted elsewhere in England, Wales, Northern Ireland and the Isle 
of Man. 
• To create a validated prognostic model using flexible parametric survival analysis techniques 







Chapter 2 Long-term survival of total hip replacements, a systematic 
review and meta-analysis 
2.1 Overview 
The definition of “long-term” follow-up in the context of THRs has changed over time and will 
continue to change in the future. This chapter seeks to assess how long a patient can expect a THR to 
last, using only openly available data. This will provide a comparator for the results of the long-term 
benchmark produced in Chapter 4. 
This article has been published in The Lancet and a copy can be found at Appendix 4. 
2.1.1 Contributors 
JTE was responsible for study concept, design, screening, data extraction, data analysis and writing of 
manuscript. RW and JPE completed the second screening of abstracts, second extraction of data and 
review of manuscript. AB and MW were responsible for study concept, design and writing of 
manuscript. AS was responsible for study concept, design, data analysis and writing of manuscript. 
2.1.2 Declaration of conflict of interests 







Total hip replacement (THR) is a common and highly effective operation. All hip replacements would 
eventually fail if in situ long enough and it is important that patients understand when this may 
happen. We aimed to answer the question “How long does a hip replacement last?”. 
A systematic review and meta-analysis were performed with a search of Medline and Embase from 
the start of records to 12th September 2017. Articles reporting 15-year survival of primary, 
conventional THR constructs in patients with osteoarthritis were included. Survival and prosthesis 
data were extracted, with all-cause construct survival the primary outcome. Reports of national joint 
replacement registries were also reviewed, and data extracted as a separate analysis. Meta-analysis 
weighted each series and a pooled survival estimate calculated for each source of data. PROSPERO 
registration: CRD42018085642. 
We identified 140 eligible articles reporting 150 series, 44 of these series (13,212 THRs) provided the 
necessary data and formed the first data set. National joint replacement registries provided data on 92 
series (215,676 THRs). The 25-year, pooled survival of hip replacements from case-series was 77.6% 
(95% CI 76.0-79.2) and from joint replacement registries was 57.9% (95% CI 57.1-58.7). 







Total hip replacement (THR) is one of the most common and effective forms of surgery, resulting in 
generally excellent outcomes (Learmonth et al., 2007). In an immortal cohort, all hip replacements 
will eventually fail due to processes such as infection, fracture or a combination of normal tribological 
and biological processes, such as loosening and wear.  
To counsel patients accurately and appropriately, benchmark treatment strategies, plan healthcare 
provision and for medico-legal purposes, it is important to know how long a THR may last. People are 
living longer and thus the long-term survivorship of the THR construct is increasingly relevant. The 
ultimate aim, that all hip replacements provide normal pain-free function for the rest of the recipient’s 
lives has not been achieved. In the UK, the National Institute of Health and Care Excellence (NICE) 
set a benchmark in 2014, that individual components making up a THR are only recommended for 
people with end-stage arthritis, if they have 10-year revision rates of ≤5% (NICE, 2014b).  
Implementation of this guidance is assisted by the Orthopaedic Data Evaluation Panel (ODEP), who 
produce summary 10-year revision rates for individual prostheses using multiple data sources. At 
present, ODEP do not publish revision rates for hip replacements, but only constituent parts.  
Patients who undergo hip replacement surgery are at risk of revision surgery. The commonest reasons 
for revision are infection, wear, loosening, dislocation, persistent pain and fracture. Revision surgery 
is not as effective as primary surgery for relieving pain and improving function and is more expensive 
(Vanhegan et al., 2012, Lenguerrand et al., 2016). Furthermore, revision hip replacements fail much 
earlier than primaries, necessitating further revisions (Hunt et al., 2018). 
The typical patient who had a hip replacement in the UK in 2016 was 69.8 years old if female, 67.6 
years old if male and had a BMI of 28.8. Ninety percent were performed for osteoarthritis and 60% of 
recipients were female (National Joint Registry for England, 2017a). Similar demographics are 
reported by the national registries in Scandinavia, Australia and the Netherlands (Australian 





Swedish Hip Arthroplasty Register 2016 Annual Report, Dutch Arthroplasty Register (LROI) 2018 
Annual Report). 
We wished to answer a very simple question that is posed to us by our patients, multiple times daily: 
“How long does a hip replacement last?” 
2.4 Methods 
2.4.1 Data source 1: Published case-series and cohort studies not from registry data 
2.4.1.1 Search Strategy 
Conduct of this systematic review and meta-analysis was by a predefined protocol registered with 
PROSPERO (CRD42018085642) adhering to PRISMA and MOOSE guidelines (Stroup, 2000, Moher 
et al., 2009). We systematically searched for case-series and cohort studies reporting survival 
outcomes of THRs in MEDLINE and EMBASE from commencement to September 2017. The search 
of Ovid Silver Platter contained keywords relating to THR, survival and MeSH terms (Appendix 5). 
Bibliographies of all full-text articles matching our criteria, as well as review articles were manually 
screened for additional citations.  
2.4.1.2 Eligibility criteria 
Studies were included if they involved predominantly unselected patients or patients undergoing THR 
for osteoarthritis (OA). Reporting of survival of a specific prosthesis, brand or construct with a mean 
or median follow-up greater than 15 years was required. Articles reviewing specifically complex 
primary THR, revision THR or hip resurfacing were excluded, as these have different survivorship. 
Conference abstracts were excluded as they were unlikely to contain enough information. Some 
articles report prosthesis construct survivorship from registry data, we excluded these as this would be 
a duplicate of data identified in data source two. Systematic reviews were retrieved, and citations 






2.4.1.3 Abstract screening and data extraction 
Journal articles were screened from their abstracts using Rayyan (Ouzzani et al., 2016) by 3 reviewers 
(JTE, RW, JPE) and in cases of disagreement, were included for review. Data were extracted by either 
JTE or JPE and RW together using a standardised proforma. Data were abstracted, when available, on 
publication date, prosthesis, fixation, number of THRs, age, sex, indication, loss to follow-up and 
summary survivorship estimates (including confidence intervals) at all time points reported, as well as 
data for quality assessment. Data were not abstracted from figures to prevent potential inaccuracy. 
Any discrepancy of data extraction was rectified by review of the full text by all three reviewers. 
There were no cases of disagreement after this. 
2.4.1.4 Statistical methods 
Our primary exposure was the THR construct and all-cause revision of any part of the construct was 
our endpoint. Statistical analysis was performed with Stata 15 (Stata Statistical Software: Release 15. 
College Station, TX: StataCorp LLC). Survival estimates, assuming survivorship approximated risk, 
were pooled with meta-analysis weighting each series on the overall pooled estimate according to its 
standard error (calculated from published confidence intervals). 
2.4.1.5 Quality assessment 
Study quality was assessed using the non-summative four-point system (consecutive cases, multi-
centre, under 20% loss to follow-up and use of multivariable analysis) developed by Wylde and 
colleagues (Wylde et al., 2017). This was selected in preference to the summative MINORS score due 
to the high loss to follow-up in joint replacement case-series and because some of the scoring criteria 
were not relevant to joint replacement (Slim et al., 2003). 
2.4.2 Data source 2:  Joint replacement registries 
The first national joint replacement registry was founded in Sweden in 1975; at the time of writing six 
registries have greater than 15 years potential follow-up for THR (Australia, Denmark, Finland, New 





replacement registries with 15 years follow-up at the time of data collection (December 2017) were 
reviewed for 15 year or greater survival data on conventional, stemmed THR constructs. These 
national registries collect data on all patients undergoing THR from both public and private hospitals 
and their aim is to include all THRs in their cohort. 
2.5 Results 
2.5.1 Data source 1:  Published case-series 
The search was performed in September 2017 and produced 4,195 references. 1,445 duplicates were 
removed, leaving 2,750 for screening. After screening, 299 full texts were left for review with 20 
additional citations identified by a manual search of references and reviews. Thirteen articles not in 
the English language, were excluded (Avedikian et al., 1996, Schmitt et al., 1996, Sorensen et al., 
1996, Soyer et al., 1997, Busch et al., 2007, Chaidez Rosales et al., 2008, Lautridou et al., 2008, 
Philippot et al., 2008, Landor et al., 2009, Rozkydal et al., 2009, Rozkydal and Janicek, 2010, Huang 
et al., 2012, Schwerter et al., 2013). Following a review of full texts, 140 journal articles reporting 
150 case-series reported survivorship of prostheses, in total these articles report on 58,932 THRs 
(range 38, 22,036). Seventy-six out of 150 case-series reported all-cause construct survival and 44 of 
these included confidence intervals (required for meta-analysis). These 44 series contributed 13,212 
THRs (range 73, 2,000) to the analyses. A flow chart of article selection can be seen in Figure 2. The 





Table 1. A full list of all contributing articles and their survival estimates can be seen at Appendix 6. 







Table 1 - Study level and participant level characteristics of contributing data sources 
 Individual case-series articles Australian Orthopaedic 
Association National Joint 
Replacement Registry 
Annual report 2017 
Finnish Arthroplasty Report 
November 2017 
Study level characteristics 
Location 42 articles in 16 countries Australia Finland 
Number of series included 44 36 56 
Year of publication 1993-2017 2017 2017 
Participant level characteristics 
Total joint replacements included 13,212 121,384 94,292 
Mean Age (years)  57.9* 67.7† 65-74‡ 
Proportion of female patients 56.2%§ 55%† 58.5%† 
Proportion of hips implanted for 
osteoarthritis 
61.8% ¶ 88.5%† Not reported 
* Weighted mean for age by number in study, † All conventional THRs in report, ‡ Exact figure not reported, median within this age range 
§ Weighted proportion of female patients by number in study ¶ Weighted proportion by number in study 
 
The 44 case-series included reported all-cause construct survival in 13,212 THRs, with duration of 
follow-up ranging from 15 to 40 years. Not all series reported survival at exactly 15, 20 or 25 years 
and some series reported survival at more than one time point. Pooled analysis of data derived from 
case-series of THRs reported at exactly 15, 20 and 25 years showed all cause survivorship of the 
construct of 85.7% (95% CI 85.0, 86.5) at 15 years, 78.8% (95% CI 77.8, 79.9) at 20 years and 77.6% 
(95% CI 76.0,79.2) at 25 years. Figure 3 shows a forest plot for meta-analysis of data derived from 











Pooled survival at each time point reported can be seen in Table 2. Survival at time points that were 
not exactly 15, 20 or 25 years are rounded down to the closest point, (to include as many series as 
possible in our analyses), pooled survival is 87.9% (95% CI 87.2, 88.5) at 15 years, (78.9% (95% CI 
77.9, 80.0) at 20 years 76.6% (95% CI 75.1, 78.2) at 25 years (Appendix 7). 
Table 2 - Pooled estimates of survival for each available time point 
Time (years) Number of 
series 
Total number of hips at 




15 12 5792 85.7 84.9-86.5 
15.9 1 104 98.9 96.7-100 
16 1 84 78.0 74.0-82.0 
17 8 1327 88.5 87.0-90.1 
18 2 159 80.5 74.9-86.0 
18.8 1 105 87.0 82.6-91.4 
19.8 1 93 79.7 70.0-88.0 
20 20 7192 78.8 77.8-79.9 
20.8 1 109 84.4 56.0-100 
22 2 386 77.3 71.8-82.8 
24.6 1 102 87.0 77.8-92.7 
25 8 4617 77.6 76.0-79.2 
27 2 1764 60.5 54.0-67.0 
30 5 2103 62.2 58.4-66.1 
35 2 423 71.7 65.0-78.3 
40 1 2000 72.0 67.0-77.0 
 
The quality assessment of the case-series revealed 54.6% of series were consecutive, none were 
multicentre, 11.4% had less than 20% follow-up and 15.9% performed multivariable analyses. This 
reflects the fact that in general, the quality of published case-series is low. 
2.5.2 Data source 2:  Joint replacement registries 
The search of joint replacement registry reports yielded 92 series, and all provided confidence 
intervals. All 92 individual construct series reported survival analyses at 15 years (215,676 THRs), 43 





derived from registry data showed all cause, construct survivorship of 89.4% (95% CI 89.2, 89.6) at 
15 years, 70.2% (95% CI 69.7, 70.7) at 20 years and 57.9% (95% CI 57.1, 58.7) at 25 years. The 15-
year data included series originating from the Australian and Finnish registries whereas the 20 and 25-
year data were exclusively from the Finnish. The other four arthroplasty registries with 15 years 
potential follow-up, did not provide survival estimates broken down by the stem/cup combination and 
therefore could not be used in our analyses. 





Table 1. Figure 4, Figure 5 and Figure 6 show forest plots for meta-analysis of data derived from joint 
replacement registry reports. A comparison of the point estimates at each time point for the two 























Figure 7 - Comparison of pooled survival estimates from case-series and registry reports at 15, 20 and 25 years 
The size of the circle representing each point estimate is proportional to the total number of hip replacements at the start of 
all the series contributing to that pooled estimate. 
 
2.6 Discussion 
Patients often ask clinicians the question: “How long will my hip replacement last?” Until now we 
have not had a generalisable answer to this question. Registry data presented here show that just over 
half of hip replacements last 25 years. Published case-series suggest better survivorship at 20 and 25 
years. The data from the two sources are similar at 15 years. Concordance at 15 years is encouraging, 
215,676 hips at start (92 series)
73,057 hips at start (43 series)
5,792 hips at start (12 series) 7,912 hips at start (20 series)
4,617 hips at start (8 series)
























but the differences at 20 and 25 years suggest that the two types of data probably have different 
sources of bias. Case-series are particularly prone to selection bias, which is not a feature of registries 
and may lead to the study population not being representative of the target population. Case-series are 
also more prone to publication bias, with clinicians and editors more likely to publicise results if 
good. Ideally, national registries capture the entire population, but in reality, are limited by the quality 
of data submitted to the registry. Case-series are usually selected and thus not necessarily 
generalisable, but if rigorously performed can have better data completeness and contain a wider set 
of variables. The smaller numbers seen in case-series compared to registries, means that loss to 
follow-up should be easier to prevent, whereas registry data is reliant on the correct linkage of a 
primary operation to the revision procedure. This may result in a form of selection bias in the registry 
data. In our review of case-series however, there was considerable variation in the number of patients 
lost to follow-up suggesting this is also a potential source of bias in case-series. We believe therefore 
that the difference in the survival estimates between the sources is in part down to the different biases 
seen between the two types of study. Regardless of potential sources of bias, we are likely to be safest 
taking the more conservative and generalisable estimates provided by the registry annual reports. 
The age and gender distribution of our studies are the same as those reported by the largest national 
registries such as the National Joint Registry for England, Wales, Northern Ireland and the Isle of 
Man (NJR) and the Swedish Hip Arthroplasty Register (SHAR) suggesting that our data is likely to be 
generalisable. Survivorship of arthroplasties correlates strongly with age, gender and prosthesis 
selection and this must be considered when counselling patients.  
Whilst our findings may be generalisable, they are also by definition historic, as there are secular 
changes in health service delivery, prosthesis design and patient characteristics. It is notable that a 
number of the components that make up the THR constructs in our analyses are no longer widely 
used. There were no articles reporting individual case-series that looked at a construct used more than 
250 times in the NJR 2016 annual report (National Joint Registry for England, 2017a). Of the 92 
registry annual report series, there were only four constructs (reported in five series) still in common 





higher 15-year survival (94.9% 95% CI 93.9-94.8). The constructs were the Exeter V40/Trident, 
Exeter V40/Exeter Contemporary Flanged, CPT/Trilogy and CPT/ZCA. The 22,589 THRs that used 
one of these combinations account for 24.5% of THR constructs implanted in England and Wales in 
2016 (National Joint Registry for England, 2017b). The forest plot for these constructs in 
contemporary use is seen at Appendix 8. The effect of using constructs with better survival should 
mean that revision rates will reduce in the future compared to the data presented here. Already overall 
revision rate by year of surgery has decreased markedly from 2008 (National Joint Registry for 
England, 2017a). 
Estimates of the lifetime risk of revision for hip replacements has been conducted using primary care 
databases (Clinical Practice Research Datalink (CPRD)) (Bayliss et al., 2017). The authors reported a 
20-year survival of 85.0% (95% CI 83.2, 86.6) from analysis of 63,158 patients with a maximum 
follow-up of 20 years. This survival estimate is higher than our 20-year estimates of 70.2% (95% CI 
69.7, 70.7) derived from registry annual reports and 78.8% (95% CI 77.8, 79.9) derived from 
published case-series. The mean age of patients in their cohort was 69 years and 62% were female, 
these are similar to the demographics seen in our data. The observed difference in estimates may be 
due to several factors, the authors used a different database (UK CPRD 1991-2011 rather than Finnish 
registry data 1980-2017), as well as using a life-table analysis method rather than the Kaplan-Meier 
estimator, employed by most authors in our data. Most notably however, were the numbers of patients 
with hip replacements at the reporting times. Bayliss and colleagues reported 20-year survival data on 
444 patients compared to the 73,057 hips with 20-year survival reported in our data. The focus of 
Bayliss and colleague’s paper was the lifetime risk of revision of a joint replacement, which is not 
what we have reported. They surmised that the lifetime risk of revision changed according to the age 
of the patient at the time the hip replacement was implanted, with older patients having a lower 
lifetime risk of revision. Our lower survival at 20 years is likely to support their conclusion that if a 
patient has a hip replacement at a younger age, then the chances of the patient having revision surgery 
are higher. There have also been several papers originating from Nordic arthroplasty registries, 





under 55 or with a particular class of hip replacement (cemented or cementless), but 2 papers 
produced generalised estimates for all hip replacements. A 2014 collaborative report from the 
combined Nordic registry, NARA (Nordic Arthroplasty Registry Association) by Makela et al, gave 
15 year survival estimates of 86% (95% CI 85.7, 86.9) in Denmark, 88% (95% CI 87.6, 88.3) in 
Sweden, 87% (95% CI 86.4, 87.4) in Norway and 84% (95% CI 82.9, 84.1) in Finland (Makela et al., 
2014).  Fevang et al’s 2010 article reported a 20-year survival estimate of 77.3% (95% CI 76.3, 78.4) 
from the Norwegian registry with 280 hips at risk at this time point (Fevang et al., 2010). 
We found heterogeneity in the reporting of case-series, notably in the handling of patients lost to 
follow-up, the point at which Kaplan-Meier survival was reported and the number of hips at risk at the 
analysis point. Guidelines exist for the reporting of observational studies (von Elm et al., 2007), it has 
been suggested these should not be used in the selection of articles for publication but act as guidance 
for inexperienced authors (Vandenbroucke, 2009). Case-series comprise a considerable proportion of 
articles both published in orthopaedic journals and presented at conferences. We feel the primary end-
point of any analysis reporting joint replacement survivorship, must be all-cause revision of any 
component of the THR construct. Whilst other endpoints, for example, revision of a single part of the 
construct or revision for a specific cause (such as aseptic loosening), were reported in series included 
in our review (Alsema et al., 1994, Aldinger et al., 2009) and may be of interest, they should only be 
reported as secondary end points, as they give a biased and unrealistic impression of survivorship. We 
have explained elsewhere, why the 1-Kaplan-Meier estimate is the most appropriate method of 
reporting survivorship (Sayers et al., 2018) (with a worst-case scenario for hips lost to follow-up) and 
must include the number of THRs “at risk” at the time of reporting. Given the observed discrepancy 
in survival, we must consider which source of information is more likely to be the true representation 
of long-term survival. National joint replacement registries are unselected and comprehensive and are 
thus more likely to give an unbiased generalisable measure of construct survivorship than case-series.  
Finally, it is important to note that failure in arthroplasty can be measured many ways and patients 
who report failure in one metric often report success using another metric. Furthermore, revision 





decide that the risks outweigh the benefits in individual cases. Failure measured by revision should 
thus be considered a best-case scenario. As the aim of surgery is to relieve pain, then a very stringent 
criterium could define failure as all patients with moderate to severe long-term pain. Beswick et al 
have shown that between 7 and 23% of patients who have not undergone revision would be regarded 
as failures using this outcome (Beswick et al., 2012). 
2.6.1 Strengths and limitations 
The main limitation of our pooled data is that they were not adjusted or stratified by patient factors 
that may play a role in determining survivorship. NJR data shows that at 10 years, construct 
survivorship in males is approximately 97% for those aged over 80 years, 96% for those aged 60-70 
years and 95% for those aged less than 60. Women have slightly better construct survivorship at all 
ages than men. Without individual patient level data, we have been unable to provide a risk estimate 
adjusted for individual characteristics such as age and gender, so our analyses provide an aggregated 
estimate for survival in all patients. Table 1 reports the demographics for each of our data sources; 
information was unavailable for the proportion of hips implanted for osteoarthritis in the Finnish 
Arthroplasty Registry. If this proportion was different to that seen in other countries, then it could be a 
source of selection bias. Poor prosthesis choices such as metal-on-metal bearings will result in 
dramatically higher revision rates (Smith et al., 2012a, Smith et al., 2012b). Peak use of metal on 
metal bearing surfaces in the NJR was in 2008 with only 404 reported in the NJR in 2003 (Smith et 
al., 2012b). The hips included in our estimates were implanted prior to 2003 and thus should be 
unaffected by the higher revision rates seen in metal on metal hip replacements. Since 2003 the 
thresholds for undertaking surgery may have changed and this could alter future outcomes. As with all 
survival reports, we cannot account for a surgeon’s willingness to revise a hip based upon individual 
patient factors. This revision threshold may change culturally between countries and affect the 
generalisability of results between nations. Our pooled annual report results only provide limited 
geographical capture, the number of THRs however, was still far in excess of that seen in individual 
case-series (215,676 THRs in registry annual reports compared to 13,212 in case-series). Data 





20 and 25 years came only from the Finnish registry. We excluded papers not in the English language 
which potentially lost 13 further series. If all these case-series were to have met the inclusion criteria, 
they may have altered our pooled results, but we expect this effect would have been small. We assume 
that survival estimates are equivalent to risks, for generating pooled estimates, and whilst the 
assumption that no censoring occurs (patients dying with a hip in situ) is clearly violated, it provides a 
useful method of aggregation in the absence of individual patient level data. When interpreting results 
of the single centre series the reader must consider the potential risk of bias from studies funded by 
industry. We did not assess in our review of articles, whether authors declared any financial interest in 
implant companies, and this is a potential source of reporting bias. It further demonstrates the 
importance of mandatory, linked registry data in providing the most accurate data possible and 
supports our use of the registry data in drawing our conclusions. The strengths of our study include an 
inclusive and comprehensive design, a priori inclusion criteria and a realistic interpretation of 
survivorship that accounts for all THR revisions and not a limited or biased subset.  
A pooled analysis of individual patient level data from all sources, would increase the numbers 
included and allow adjustment for age sex and indication. 
2.7 Conclusion 
Pooled survival derived from case-series, appear to show a more optimistic estimate than pooled 
registry data, given this and the bias inherent to published case-series, we believe registry data to be 
the safer estimate. There is not enough information yet available to tell us exactly how long a hip 
replacement lasts, however, using available arthroplasty registry data, about three quarters of hip 
replacements last fifteen to twenty years and just over half of hip replacements last twenty-five years, 





Chapter 3 Generalisability and reproducibility of survival estimates 
from an exemplar centre 
3.1 Overview 
Chapter 4 of this thesis aims to use information from the Princess Elizabeth Orthopaedic Centre, 
Exeter (PEOC) local database to predict the long-term revision rate of THRs recorded in the NJR. 
This relies on the assumption that THRs implanted in PEOC demonstrate similar survival patterns to 
those implanted elsewhere in the UK. This chapter investigates the generalisability of survival 
estimates created from this single centre. It further examines whether any observed differences are 
due to a centre effect or other factors, such as prostheses selection. 
An article based on this work titled “Incisions or decisions? Are “better than expected” surgical 
outcomes a centre effect or secondary to prosthesis decisions? Findings from the National Joint 
Registry for England, Wales, Northern Ireland and Isle of Man (NJR)” has been submitted for 
consideration for publication. 
3.1.1 Contributors 
JTE was responsible for study concept, design, data analysis and writing of manuscript. MJW and AT 
were responsible for study concept, design and review of manuscript. AB and MRW were responsible 
for study concept, design and writing of manuscript. AS was responsible for study concept, design, 
data analysis and writing of manuscript. 
3.1.2 Declaration of conflict of interest 
JE, AB, AS and MRW have no conflict of interest to declare. MJW and AT receive royalties from 
Stryker orthopaedics in relation to intellectual property. They also receive institutional support in 






Analysis of arthroplasty registry data shows that few units achieve results better than 99.98% control 
limits. Prosthesis selection is considered a predictor of outcome variation in joint replacement. We 
analysed the outcomes of a unit with statistically “better than expected” results and compared to all 
other units within the National Joint Registry for England, Wales, Northern Ireland and Isle of Man 
(NJR). We sought to determine whether improved prosthesis survival following primary total hip 
replacement (THR) is a centre effect or mediated by prosthesis selection.  
We identified 664,761 THRs in the NJR. The exposure was the unit in which the THR was implanted 
and the outcome all-cause revision. Net failure was estimated using Kaplan-Meier and adjusted 
analyses used flexible parametric survival analysis. 
The crude 10-year revision rate for THRs was 1.7% (95% CI: 1.3, 2.3) in the exemplar centre and 
2.9% (95% CI: 2.8, 3.0) elsewhere (log rank test P<0.001). Of 6,230 THRs performed in the exemplar 
centre, 99.9% used the same femoral stem. After restricting analyses to this stem, crude survival from 
other units was 2.3% (95% CI: 2.2, 2.4) (log-rank test p=0.05). Age and sex adjusted analyses, 
restricted to the same stem/cup combinations as the exemplar centre, show no demonstrable 
difference in restricted mean survival time between groups (p=0.28). 
These results suggest the “better than expected” performance of an exemplar centre may be replicated 
by adopting key treatment decisions, such as prosthesis selection. These decisions are easier to 
replicate than technical skills or system factors. This is an important and easily applicable lesson for 








The variations present in the outcomes of healthcare are of keen interest to patients, practitioners and 
policy makers across all areas of medicine. Sources of variation can be attributed to factors associated 
with the patient, intervention, treating healthcare professional or treatment centre. Replicating the 
determinant factors in achieving the best observed results should lead to consistent delivery of 
excellent care and value for money.  
Surgery is one area of medicine where performance monitoring is well established. In the United 
Kingdom, performance monitoring increased following significant and well documented failings in 
healthcare systems, including the Bristol Royal Infirmary (heart) Inquiry, and the 3M Capital Hip 
System (Muirhead-Allwood, 1998, Kennedy, 2001, The Royal College of Surgeons of England, 
2001). One of the results of these events was the creation of the National Joint Registry for England 
and Wales (NJR) for the continuous monitoring of the performance of hip and knee replacements. 
Most performance monitoring focusses on identifying poor performance; understanding and 
replicating excellence is often ignored. Total hip replacement (THR) is one of the most successful 
surgical interventions and provides pain relief and improved function to hundreds of thousands of 
patients every year worldwide (Learmonth et al., 2007). Hip replacements last approximately 25 years 
(Evans et al., 2019), yet there is marked variation with some centres and surgeons achieving 
substantially better results than others (National Joint Registry for England, 2018a). 
In 2017, the NJR recorded 91,698 primary THRs carried out in 415 different hospitals (National Joint 
Registry for England, 2018a, National Joint Registry for England, 2018c). Despite the frequency and 
regularity of procedures, over 822 different THR stem/cup combinations were used indicating a large 
variation in practice (National Joint Registry for England, 2018b). 
THRs can fail for a variety of reasons, commonly infection, wear, loosening, dislocation, persistent 
pain or fracture (National Joint Registry for England, 2018a). When this happens, they require 





(Vanhegan et al., 2012, Lenguerrand et al., 2016, Hunt et al., 2018). In England and Wales the 
“Getting It Right First Time” (GIRFT) initiative has suggested that prosthesis choice is, at least in 
part, responsible for this variability (Briggs, 2015). A theory that is supported by recent work from 
Deere and colleagues demonstrating the variation in survival between different prosthesis 
combinations (Deere et al., 2019).  
Each year the NJR publishes an annual report documenting the survivorship of different prosthesis 
combinations as well as identifying centres with “better than expected” performance for revision 
rates. Some of the best performing prosthesis combinations listed in the NJR consist of a construct 
consisting of the Exeter V40 femoral stem (Stryker Orthopaedics, Mahwah, New Jersey) combined 
with one of several acetabular components, resulting in revision rates of less than 2.5% at 10 years for 
the most popular combinations. This revision rate is under half that of the benchmark standard of 5% 
suggested by the National Institute for Health and Care Excellence (NICE) and the Orthopaedic Data 
Evaluation Panel (ODEP). The Royal Devon & Exeter NHS Foundation Trust, Wonford is home to 
the Princess Elizabeth Orthopaedic Centre (PEOC); this unit was identified in the 15th NJR Annual 
Report as being one of only three centres with outcomes better than the 99.98% control limits, in 
analysis of both all (since 2003) and contemporary (since 2013) data. In this centre, the Exeter V40 
stem is almost exclusively used for all primary THRs regardless of age and indication. If patients 
treated at PEOC are comparable to those treated in other units, this suggests that patient factors are 
unlikely to mediate the outcomes observed due to lack of selection.  
We aimed to compare the net failure (Sayers et al., 2018) of THR constructs implanted at a unit with 
“better than expected” performance to all other units within the NJR, to determine if the observed 
differences in performance were centre mediated or an prosthesis selection effect. 
3.4 Methods 
The dataset consisted of 981,269 linked primary THRs performed in England and Wales between 1st 
April 2003 and 31st December 2017 with consent for data linkage. Data were censored either by death, 





data or using metal-on-metal bearings, we were left with 664,761 primary THRs, where osteoarthritis 





Table 3 - Reasons for exclusion from analyses 
 Procedures excluded (n) Procedures remaining (n) 
All procedures in NJR  2,346,340 
Cases without consent 302,670 2,043,670 
All hip procedures 1,062,401 981,269 
Sequences* with duplicates, inconsistent sequences, records currently 
in edit 
13,569 967,700 
Sequences starting with a revision 62,735 904,965 
Survival less than 0 years 36 904,929 
Age over 110 years 31,577 873,352 
Operation date recorded as before start of NJR 6 873,346 
Age under 0 years 1 873,345 
Revision procedures 25,998 847,347 
Not primary THR (e.g. resurfacing) 46,515 800,832 
Sequences with indications other than OA 82,702 718,130 
Non-unique prosthetic constructs 28,803 689,327 
Metal on metal bearing 24,566 664,761 
Total data set  664,761 
* A sequence is the order of operations recorded in the NJR for any patient. All complete records will start with a primary operation. If a sequence starts with a revision, 





3.4.1 Statistical analyses 
Statistical analysis was performed with Stata 15 (Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC). The exposure of interest was the unit in which the THR was performed 
and the two groups are: 
1. THRs performed at the exemplar centre 
2. THRs performed in any other unit 
The outcome of interest was all-cause revision, as guided by the Patient Experience in Research group 
at the University of Bristol (Gooberman-Hill et al., 2013). All-cause revision was defined using the 
NJR definition as “the addition, removal or modification of any part of the construct”. The study 
population was all THRs implanted in the NJR; sub-group analysis was performed for THRs using 
any type of cemented stem (hybrid or all-cemented constructs) as well as THRs using the same 
femoral stem as the exemplar centre (hybrid or all-cemented constructs).  
Unadjusted survival estimates were calculated using the Kaplan-Meier (KM) method for all included 
THRs, stratified by the exposure of interest (Kaplan and Meier, 1958). Flexible parametric survival 
analysis (FPSA), as described by Royston and Parmar, was used to look for time varying effects in the 
two exposure groups by plotting time-dependent against proportional hazards models (Royston and 
Parmar, 2002). FPSA models were then used to compare THRs performed at the exemplar centre to 
THRs performed in any other unit, having adjusted for age and sex and allowing for time varying 
effects. FPSA models were assessed visually for goodness of fit against KM curves, in THRs using 
the same femoral stem as the exemplar centre. Graphs comparing survivorship between the two 
exposure groups were fitted to models for a 68-year-old female patient, to reflect the median age and 





3.4.2 Sensitivity analyses 
Where time period specific differences in revision rates between the groups persisted, despite 
restriction by femoral stem selection, analyses were restricted by indication for revision, to explore 
the reasons for the difference. In addition, revision rates were explored restricting analyses to only 
THRs using the same stem and cup prostheses as the exemplar centre. Construct survival of THRs 
using the five most commonly implanted cemented stems were explored to determine if the observed 
results are unique to a particular prosthesis or whether similar results could be achieved with other 
commonly used prostheses within the same types of construct fixation. 
3.5 Results 
Of the 664,761 THRs included, there were 385,919 (58%) cemented or hybrid constructs and 235,041 
(35%) used the same femoral stem as the exemplar centre. No cases were missing data on unit or type 
of stem fixation. There were 224 THRs where the brand of stem was not recorded, none of these were 
performed at the exemplar centre. There were 6,230 primary THRs performed at the exemplar centre 
during this period and the same femoral stem was used as part of the construct in 6,227 of these 
(99.9%). Only three cases used other stems. The maximum follow-up in the exemplar centre group 
was 13.9 years and was 14.2 years in all other units. The demographics and distribution of the THRs 





Table 4 - Demographics and distribution of included THRs 
 
All THRs Constructs using a cemented stem 
Constructs using the same femoral stem as the 
exemplar centre 
Operated on at the 
exemplar centre 
Not operated on at the 
exemplar centre 
Operated on at the 
exemplar centre 
Not operated on at 
the exemplar centre 
Operated on at the 
exemplar centre 
Not operated on at 
the exemplar centre 
Total n 6,230 658,531 6,228 379,691 6,227 228,814 
Female n (%) 3,621 (58.1) 402,406 (61.1) 3,619 (58.1) 245,891 (64.8) 3,619 (58.1) 146,219 (63.9) 
Mean Age (SD) 70.2 (10.6) 69.9 (10.1) 70.2 (10.6) 72.5 (9.2) 70.2 (10.6) 72.1 (9.3) 
Mean BMI, kg/m2 (SD) 28.6 (5.2) 28.7 (5.2) 28.6 (5.2) 28.4 (5.1) 28.6 (5.2) 28.5 (5.1) 
Posterior approach n (%) 5,553 (89.1) 377,802 (57.4) 5,552 (89.1) 208,652 (55.0) 5,551 (89.1) 136,090 (59.5) 
ASA n (%) 
I 963 (15.5) 98,212 (14.9) 963 (15.5) 48,189 (12.7) 963 (15.5) 29,987 (13.1) 
II 4,499 (72.2) 462,006 (70.2) 4,497 (72.2) 265,746 (70.0) 4,496 (72.2) 159,682 (69.8) 
III 756 (12.1) 95,507 (14.5) 756 (12.1) 63,868 (16.8) 756 (12.1) 38,050 (16.6) 
IV & V 12 (0.2) 2,806 (0.4) 12 (0.2) 1,888 (0.5) 12 (0.2) 1,095 (0.5) 
NHS Funded n (%) 6,123 (98.3) 552,907 (84.0) 6,121 (98.3) 317,950 (83.7) 6,120 (98.3) 193,566 (84.6) 
Consultant as operating 
surgeon n (%) 
3,004 (48.2) 546,315 (83.0) 3,002 (48.2) 302,394 (79.6) 3,001 (48.2) 184,886 (80.8) 





3.5.1 Crude analyses 
The crude 10-year revision rate of all THRs implanted at the exemplar centre was 1.7% (95% CI: 1.3, 
2.3). All but three THRs implanted in the exemplar centre during the period of study, used the same 
femoral stem and none of the remaining three cases have been revised, so this figure does not change 
in either subgroup (THRs using a cemented stem or THRs using the same femoral stem as the 
exemplar centre). The 10-year revision rate was 2.9% (95% CI: 2.8, 3.0) for all THRs in other units 
(log rank test P<0.001), for THRs using cemented stems it was 2.6% (95% CI: 2.5, 2.7) (log rank test 
P<0.05) and for THRs using the same femoral stem as the exemplar centre, it was 2.3% (95% CI: 2.2, 
2.4) (log rank test p=0.05). 1-Kaplan-Meier curves, estimating net revision can be seen in Figure 8; a 
table detailing the number of hips at risk at all time points for all analyses can be seen in Appendix 9. 






3.5.2 Adjusted analyses 
An FPSA model was fitted for all THRs using the same femoral stem as the exemplar centre and 
showed excellent “goodness of fit” (see Appendix 10). After adjustment for age and sex and allowing 
for time varying effects, the relative revision estimates of each subgroup of THRs modelled for a 68-
year-old, female patient, are shown in Figure 9a, b and c.  
To explain the early differences in revision rate between the two groups, analyses were restricted by 
reasons for revision. The combined model censoring revisions for instability and infection appears to 
reduce the difference in the early period most effectively and can be seen in Figure 9e.  
The femoral stem was paired with nine different acetabular components at the exemplar centre, 99% 
of these THRs used one of three cups (Exeter Contemporary Flanged, Exeter X3 Rimfit or Trident) 
with the Exeter Contemporary Flanged the most frequently used (n=3,227; 52%). In other units, the 
same femoral stem as used by the exemplar centre was paired with 111 different acetabular 
components, again with the Exeter Contemporary Flanged the most frequently used (n=57,074; 25%). 
Figure 9d shows a comparison of the two groups if analyses are restricted to stem/cup combinations 
used at the exemplar centre. Once this restriction is placed on analyses the dataset is reduced to 
148,295 THRs outside the exemplar centre. At 13.9 years there is a difference in restricted mean 
survival time (RMST) of 0.03 years (95% CI: -0.02, 0.07, P=0.28), suggesting very little evidence 
against the null hypothesis that there is no difference in RMST between THRs implanted in the 
exemplar centre and those implanted elsewhere. Figure 10 demonstrates how the difference in RMST 











Figure 10 - Difference in restricted mean survival time with prostheses restricted to those used in the exemplar centre. 
 
3.5.3 Sensitivity analyses 
Figure 9f shows only THRs using the same stems and cups as the exemplar centre, having censored 
revisions for instability and infection. 
All cause-construct survival of THRs using one of the five most commonly implanted cemented stems 
show that other stems may achieve comparable performance to the one used at the exemplar centre, 
but this is not true of all stems with the same mode of fixation (see Appendix 12). 
3.6 Discussion 
This study suggests that in the context of a generalisable national registry, “better than expected” unit 
performance may be replicated across other units simply by using the same prostheses. We have 
established that the “better than expected” performance, in this context, is driven primarily by 





This analysis of NJR data, shows a significantly better all-cause revision rate at 10 years for THRs 
performed at the exemplar centre, compared to all other units combined (1.7% compared to 2.9%). 
This significant difference reduces when constructs are limited to those using a cemented stem and 
then further attenuates when analyses are limited to constructs using the femoral stem used almost 
universally in the exemplar centre. KM estimates suggest revision rates in the two groups vary over 
time and this is supported by an assessment of proportionality of hazards (Appendix 11). The use of 
FPSA, enables us to model time dependent effects when comparing the two groups, after adjustment 
for age and sex. Adjusted analyses show lower relative revision rates in THRs implanted in the 
exemplar centre for the first four years, but comparability thereafter, up to approximately 10 years. 
Once instability and infection are censored as indications for revision, this early gap attenuates, 
suggesting the observed difference is at least in part, due to factors that influence the risk of revision 
for these indications. Instability and infection are the third and fifth most common reasons for revision 
reported in the 15th NJR annual report and exclusion of them is solely to identify the potential reason 
for a difference and further conclusions should not be drawn (National Joint Registry for England, 
2018a). Restriction of the dataset, to only include constructs using the same prostheses as the 
exemplar centre, suggests there is no difference in RMST between THRs implanted in the exemplar 
centre and elsewhere (P= 0.28) if the same THR constructs are used. 
The pursuit of improved outcomes in healthcare causes many to turn to innovation, such as the use of 
new prostheses, surgical techniques or robotics, that may or may not have proven benefits. This is 
reflected in the large number of different stem/cup combinations recorded by the NJR (n=822). 
Innovation is not always of benefit as was well demonstrated by the widespread and rapid adoption of 
metal-on-metal bearings in THR which were associated with much higher revision rates than 
alternative bearings (Smith et al., 2012b, Hunt et al., 2018). We suggest that, in a field with 
considerable variation in outcomes, the simplest and potentially lowest risk option may be to copy the 
prosthesis decisions made by centres already displaying “better than expected” outcomes. Centres 
with such outcomes are already identified in this setting, by the comprehensive and mandatory NJR. 





interactions of factors in healthcare settings or variations in surgical technique that this analysis 
suggests are not the most important determinants of outcome. 
Our analyses were based on one of three units highlighted by the NJR 2018 annual report as having 
contemporary “better than expected” performance, using data since 2013. The choice of unit was 
principally due to the absence of selection bias in the choice of THR stem in this centre, but also 
because of permission to access data to perform the analysis. Of the 6,230 THRs in our dataset 
performed at the exemplar centre, 6,227 (99.9%) used the same femoral stem and this all but 
eradicates selection bias in this group. If a selection bias effect is present in the “rest of the NJR” 
group, we would expect it to improve survival relative to the exemplar centre as the patients “most 
suitable” for a cemented stem should have been selected. A higher proportion of THRs were 
performed using the “posterior approach” to the hip joint in the exemplar centre (Table 4) and it is 
possible that this could be a factor in the improved survival outcomes. It was felt that this variable 
should not be included as a potential confounder in controlled analyses, as it is potentially on the 
causal pathway between implant choice and revision and would yield biased or inaccurate results. The 
main strengths of this study include the high numbers of THRs included, the a priori, binary outcome 
measure guided by our patient group and the use of a mandatory national linked database with a clear 
definition of revision to identify revision procedures. Table 4 demonstrates the differences between 
THRs performed in the exemplar centre and all other units and of note a lower proportion of cases 
were performed by a Consultant surgeon in the exemplar centre. This further supports our hypothesis 
of the pre-eminence of implant decisions over surgical skill (with level of surgeon acting as a proxy in 
this example). 
This study demonstrates that revision rates observed in a centre with “better than expected” 
performance, after adjustment for age and sex, are achieved cumulatively by all units when using the 
same prosthesis construct combinations. A strategy of using the same prostheses as a centre with 
“better than expected” performance is a quick and easy way of improving outcomes for many 






The “better than expected” performance observed in an exemplar centre may be replicated, through 





Chapter 4 Creation of a prognostic model for long-term survival of 
THRs using the database held by the Exeter hip unit 
4.1 Overview 
Given the results of Chapter 3, that suggest the survival estimates of THRs performed in the Princess 
Elizabeth Orthopaedic Centre, Exeter (PEOC) are generalisable to the rest of the NJR; it is reasonable 
to go on to use the data from the local long-term database to make predictions for THRs recorded in 
the NJR. This chapter uses the PEOC database to create a predictive algorithm that is then applied to 
the whole NJR, as an out of sample estimate. This gives a forecast of the long-term survival of THRs, 
assuming the same contemporary prosthesis combinations as used in PEOC and recorded in the local 
database were used. The prediction has then been validated against the actual survival data seen in the 
NJR for THRs using the same prosthesis combinations to the maximum follow-up period available in 
the NJR. 
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Total hip replacements (THR) provide pain relief and improved function to thousands of patients 
suffering from end-stage hip osteoarthritis (OA), every year. Given time, all THRs will fail, and the 
variation in survival between different prostheses has been demonstrated. In 2017, there were 822 
different combinations of stem and cup implanted in England and Wales. To encourage the use of 
prostheses with high survival, the National Institute for Health and Care Excellence (NICE) sets a 
benchmark that prostheses should only be used if fewer than 5% are expected to fail after 10 years. 
Given the 10-year cumulative mortality of patients under 55 years of age receiving THRs is only 5%, 
we aim to produce extended benchmarks out to 30 years. 
The local database of the Princess Elizabeth Orthopaedic Centre (PEOC) holds data on over 20,000 
patients with follow-up of nearly 30 years for contemporary prostheses. Via flexible parametric 
survival analysis, we created an algorithm using this database, for revision of any part of the 
construct, controlling for age and gender. This algorithm was applied to 664,761 patients in the 
National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) who have 
undergone THR for OA, producing a revision prediction for patients with the same prostheses as 
those used at this centre and recorded in the local database. 
Using our algorithm, the 10-year predicted revision rate of THRs in the NJR was 2.2% (95% CI 1.8, 
2.7) based on a 68-year-old female patient; well below the current NICE benchmark. Our predictions 
were validated by comparison to the maximum observed survival in the NJR (14.2 years). The 
predicted revision rate after 30 years is 6.5% (95% CI 4.5, 9.4). The low observed and predicted 
revision rate with the prosthesis combinations studied, suggest current benchmarks may be lowered 







Almost 100,000 primary total hip replacements (THRs) were performed in England and Wales in 
2017 (National Joint Registry for England, 2018a) with the aim of providing pain relief and/or 
improved function to patients (British Orthopaedic Association, 2012). Given time, all THRs will fail 
often resulting in the need for revision surgery, which is costly and less effective than primary surgery 
(Lenguerrand et al., 2016, Hunt et al., 2018). Several factors may affect how long an individual 
primary THR will last, including the age and sex of the patient (at the time of operation), as well as 
which prostheses were implanted (Bayliss et al., 2017). Considerable variation has been observed in 
the survival of different THR constructs (combinations of prostheses) within the National Joint 
Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) (Deere et al., 2019).  
The National Institute for Health and Care Excellence (NICE) provides a benchmark for the survival 
of prostheses, but only at 10 years and for individual prostheses rather than the whole THR construct. 
The current NICE benchmark states that “Prostheses for total hip replacement and resurfacing 
arthroplasty are recommended as treatment options for people with end-stage arthritis of the hip only 
if the prostheses have rates (or projected rates) of revision of 5% or less at 10 years.” (NICE, 2014b). 
Surgeons and patients are supported in their choice of THR components by prosthesis survival ratings 
published by the Orthopaedic Data Evaluation Panel (ODEP). The NICE benchmark at 10 years was 
based on a study of nine-year data from the NJR (Kandala et al., 2015). At the time of writing, the 
NJR holds follow-up data of up to 14.2 years (National Joint Registry for England, 2018a). 
Before national joint replacement registries, surgeons and patients were almost solely reliant on 
published reports of case-series for information on the survival of THR prostheses. These case-series 
were and still are frequently based on large, long-term databases held at individual hospitals or 
research units. The Princess Elizabeth Orthopaedic Centre, Exeter (PEOC) is the designer centre of 
the most commonly used femoral component in the NJR (National Joint Registry for England, 
2018b). The PEOC database hold records of patients undergoing THR since before the introduction of 





implanted at PEOC since 1st January 1988 and an Exeter V40 stem used for all primary THRs since 
19th December 2000. In 2016, the survival of the first 382 consecutively implanted Exeter Universal 
stems was reported at 22.8 years of follow-up using information from this database (Petheram et al., 
2016). The Exeter V40 femoral component was introduced as an update of the Exeter Universal stem 
after adaptations to the taper of the trunnion. It has been suggested that to date, the Exeter V40 stem 
has displayed similar survival characteristics to its predecessor (Westerman et al., 2018). It is 
important however to test this theory with sensitivity analyses when grouping the two stems together 
for research purposes. In general, the long-term follow-up of prostheses is limited by the introduction 
of new technology and the subsequent secular changes in prosthesis use.  
Comparisons between PEOC and the rest of the country using NJR data, have suggested that the 
“better than expected” survival results observed in PEOC (National Joint Registry for England, 
2018a) may be due to prosthesis choices rather than local or technical factors (Chapter 3). This work 
also suggests that THR survival results from PEOC are generalisable to the rest of the country if an 
Exeter V40 stem is used in conjunction with an Exeter Contemporary Flanged, Rimfit or Trident cup. 
The NJR 2018 annual report suggests that patients under 55 have only a 5% chance of death for any 
reason after 10 years (National Joint Registry for England, 2018a) which is the limit of the current 
benchmark. Recent evidence from national joint replacement registries suggests that 58% of hip 
replacements will still be in situ after 25 years (Evans et al., 2019). Given this information, we aimed 
to use the PEOC database in combination with the NJR, to create extended benchmarks for the 
survival of a THR construct out to 30 years. 
4.4 Methods 
All 22,008 THRs entered into the PEOC database between 1st January 1988 and 31st December 2017 
were included in this study. The outcome was all cause revision of any part of the construct, as guided 
by the Patient Experience in Research group at the University of Bristol (Gooberman-Hill et al., 
2013). After exclusion of revision procedures, those with incomplete sets of prosthesis components 





18,144 THRs remained. The full list of exclusions can be seen in Table 5. The overall PEOC database 
provided a maximum follow-up of 29.8 years (mean 9.3 years) on all THRs. The maximum follow-up 
for THRs using an Exeter Contemporary Flanged, Rimfit or Trident cup was 18.8 years (mean 6.5 
years).  
Table 5 - Reasons for exclusion from analyses 
 Procedures excluded (n) Procedures remaining (n) 
All procedures in PEOC database  22,008 
Duplicates 118 21,890 
Revisions 3,185 18,705 
Operation type missing 9 18,696 
Stem details missing 231 18,465 
Cup details missing 293 18,172 
Died before operation 22 18,150 
THR in situ >100 years 1 18,149 
Missing gender 5 18,144 
Total data set  18,144 
 
The 18,144 THRs in our study comprised of 6,553 (36.1%) using the Exeter Universal and 11,591 
(63.9%) using the Exeter V40 stem. Overall, there were 18 different acetabular components used and 
11,100 (61.2%) THRs used either an Exeter Contemporary Flanged, Rimfit or Trident cup.  
Statistical analyses were performed in Stata 15 (Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC). Survival analyses were completed using Kaplan-Meier for unadjusted 
estimates and flexible parametric survival analysis (FPSA) for estimates adjusted for co-variates 
(Kaplan and Meier, 1958, Royston and Parmar, 2002). Confidence intervals for unadjusted (crude) 
estimates were calculated using the method described by Kalbfleisch and Prentice (Kalbfleisch and 
Prentice, 2002). An endpoint of revision of any part of the construct for any reason was used 
throughout. Sub-group analysis was performed for THRs that used any one of the three cups shown in 
Chapter 3 to be generalisable (when paired with the Exeter V40 femoral stem) to the rest of the 





performed of only the THRs with the generalisable cups when used in combination with the Exeter 
V40 stem to avoid the assumption that it performs in the same manner as the Exeter Universal stem. 
The co-variates of age and sex (at time of operation) were used for the adjusted model as these are 
well established confounders of THR survival (Bayliss et al., 2017, Deere et al., 2019) and used by 
the NJR in the calculation of potential outliers (NJR Adopted Statistical Methodology for Potential 
Outlier Identification). After assessment of log-likelihood, a flexible parametric survival model with 4 
knots was chosen for use with the stpm2 package within Stata (Lambert and Royston, 2009), as this 
provided the best combination of goodness of fit and parsimony. Appendix 13 depicts the goodness of 
fit of the model. Predictions were based on a female patient aged 68 to reflect the most common sex 
and median age of patients in the NJR (National Joint Registry for England, 2018a).  
The algorithm derived from the PEOC database was then applied to the dataset previously used in 
Chapter 3, to make an out of sample estimate of survival for the patients who had THRs recorded in 
the NJR using any prostheses. The maximum follow-up of patients in the NJR was 14.2 years. The 
exclusions and numbers included in the NJR dataset can be seen in Table 3. Estimates were 
extrapolated to 30 years.  
4.4.1 Validation 
Validation of predictions was performed using restricted mean survival time (RMST) (Royston, 2017) 
by comparing against observed revision rates in the NJR of THRs using the same construct 
combinations. 
4.4.2 Sensitivity analysis 
The PEOC database is not linked to either the Office for National Statistic (ONS) database or the NJR 
for identifying cases of death or revision. Instead, the local research team identifies these cases when 
patients are due to be called for follow-up appointments or when a revision operation happens in 
PEOC. Case-series published by the Exeter Hip unit frequently use a sub-set of the overall database 
and prior to publication, the accuracy of all variables (including date of death and whether revision 





research projects are likely to be more accurate than the overall database, albeit with fewer patients. 
The article by Petheram et al., looking at the survival of the first 382 Exeter Universal stems, is one 
such example (Petheram et al., 2016). To assess the accuracy of our overall estimates using the entire 
database, a sensitivity analysis was performed using just the Petheram 2016 dataset to create a 
separate algorithm. 
4.5 Results 
After exclusions (Table 5), 18,144 THRs remained in the database, and these formed the basis of 
analyses. The demographics of included patients can be seen in Table 6.  
Table 6 - Demographics of patients in PEOC database 
 
All THRs in PEOC 
database 
THRs in PEOC database 
using generalisable cups* 
THRs in PEOC database using 
generalisable cups* and Exeter 
V40 stem 
Total n 18,144 11,100 11,003 
Female n (%) 11,013 (60.7) 6,552 (59.0) 6,499 (59.1) 
Mean age (SD) 69.3 (11.7) 69.2 (11.8) 69.2 (11.8) 
Posterior approach n (%) 15,668 (86.4) 10,868 (97.9) 10,774 (97.9) 
Cemented acetabulum n (%) 11,988 (66.1) 8,659 (78.0) 8,598 (78.1) 
Consultant as operating surgeon 
n (%) 
6,460 (35.6) 4,609 (41.5) 4,562 (41.5) 
* Contemporary Flanged, Rimfit & Trident acetabular components 
The number of THRs entered into the PEOC database each year is seen in Figure 11. A figure 
showing the use of generalisable cups as part of the construct, as well as one demonstrating the use of 





Figure 11- Number of THRs entered into PEOC database each year 
 
Using the entire PEOC dataset, the survival at 25 years calculated with Kaplan-Meier estimates was 
88.5% (95% CI 87.2, 89.6) with 485 hips “at risk”. Full Kaplan-Meier plots for all THRs and just 





























Figure 12 - Revision estimate (1-KM) of all hips in PEOC database 
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When the algorithm derived from the 11,100 THRs with generalisable cups is applied to the patients 
in the NJR as an out of sample estimate, 6.5% (95% CI 4.5, 9.4) of hips are predicted to be revised 
after 30 years. The equivalent graph based on an algorithm using all THRs in the PEOC database is 
available in Appendix 16. 
The extrapolated 30-year estimate seen in Figure 14 is based on 18.8 years of data and based on an 
algorithm derived from all Exeter Universal or Exeter V40 stems paired with a generalisable cup. The 
equivalent graph based on the algorithm using only the Exeter V40 stem can be seen in Appendix 17 
as can a graph comparing the two algorithms (Appendix 18). There appears to be very little difference 
between the two algorithms at all time points, this is likely because the Exeter V40 stem was brought 
in shortly after the Contemporary Flanged and Trident acetabular components. As a result, a very 
small proportion of the Exeter Universal stems contribute to the algorithm. Survival at different time 
points from both the observed data and algorithm can be seen in Table 7. A corresponding table for 





Figure 14 - Predicted probability of revision of THRs in the NJR based on algorithm derived from THRs using an Exeter 
Universal or Exeter V40 stem paired with a generalisable cup in the PEOC database 
 
Table 7 - Point survival estimates from observed data and prognostic algorithm  
Time point (years) Observed survival 
from PEOC database. 
Number of THRs at 
risk in PEOC database 
Algorithm predicted 
revision rate* 
Observed survival in NJR* 
5 1.3% (95% CI 1.1, 1.5) 6,382 1.2% (95% CI 1.0, 1.5) 1.3% (95% CI 1.2, 1.4) 
10 2.2% (95% CI 1.9, 2.6) 2,451 2.2% (95% CI 1.8, 2.7) 2.4% (95% CI 2.2, 2.6) 
15 3.4% (95% CI 2.7, 4.2) 300 3.3% (95% CI 2.6, 4.1)  
20   4.3% (95% CI 3.3, 5.8)  
25   5.4% (95% CI 3.9, 7.5)  
30   6.5% (95% CI 4.5, 9.4)  
* Algorithm based on THRs using Exeter Universal or Exeter V40 stem with generalisable cups, modelled for 68-year-old female patient 
4.5.1 Validation 
There was no demonstrable difference in RMST between our predictions and what was observed in 





Table 8 - Comparison of Restricted Mean Survival Time (RMST) between predictions and observed NJR data 
Time point (years) Difference in RMST (years) 
to 2 decimal places 
Standard error of difference 
in RMST to 2 decimal places 
P value 
1 <0.01  <0.01 0.61 
2 <0.01 <0.01 0.62 
3 <0.01 <0.01 0.82 
4 <0.01 <0.01 0.98 
5 <0.01 <0.01 0.90 
6 <0.01 0.01 0.79 
7 <0.01 0.01 0.69 
8 <0.01 0.01 0.60 
9 <0.01 0.01 0.53 
10 0.01 0.01 0.47 
11 0.01 0.02 0.42 
12 0.02 0.02 0.38 
13 0.02 0.02 0.35 
14 0.02 0.03 0.33 
14.2 (all NJR data) 0.03 0.03 0.32 
 
4.5.2 Sensitivity analysis 
Comparison of the algorithm derived from the sensitivity analysis dataset is seen in Appendix 19. The 
lower numbers lead to wider confidence intervals, however the estimate based on the larger database 
and observed NJR results both fall within its confidence intervals at all time points. It should be noted 
however that the THRs included in the Petheram 2016 dataset used cups other than the three shown to 
be generalisable in Chapter 3, casting doubt over its usefulness as a comparator dataset. 
4.6 Discussion 
In this study, based upon the assumption that THRs performed in PEOC are generalisable to the rest 
of the country (when using certain combinations of prostheses), we have predicted the 30-year 
revision of THRs in the NJR using an Exeter V40 or Exeter Universal stem with a Contemporary 
flanged, Rimfit or Trident cup to be 6.5% (95% CI 4.5, 9.4). These predictions have been validated 
against the same construct combinations for the full length of follow-up held in the NJR at the time of 
analysis (14.2 years). This represents excellent survivorship when compared to published results and 





There are few case-series or other sources of data that have been published with similar lengths of 
follow-up to this study and none have attempted to use these databases to predict national THR 
survival in a generalisable cohort with contemporary prostheses. A handful of studies report long-term 
survival estimates for cemented THRs. In 2007, Wroblewski and colleagues reported the survival of 
all THRs using a Charnley low-friction arthroplasty performed at Wrightington Hospital between 
November 1962 and June 2005 (Wroblewski et al., 2007). The study included 22,066 THRs with a 
maximum follow-up of 38 years and reports a revision rate for “all complications” at 31 years (with 
40 THRs at risk) as 70%. The survival of Charnley THRs at 25 and 35 years is also reported in studies 
by Berry and colleagues and Callaghan and colleagues respectively (Berry et al., 2002, Callaghan et 
al., 2009). Berry reports a 25-year revision rate of 19.1% (95% CI 17.0, 25.1) in a cohort of 2,000 
THRs with a minimum of 25 years follow-up. Callaghan and colleagues followed THRs for a 
minimum of 35 years and with 15 THRs at risk at 35 years observed an all cause construct revision 
rate of 22% (95% CI 14, 30). These reported revision estimates of THRs using a Charnley stem are 
higher than our predictions using an Exeter stem implanted in conjunction with the cups used in our 
analyses. The article published by Petheram and colleagues, used as a sensitivity analysis in this 
study, reported a 17.1% (95% CI 11.6, 22.2) all cause construct revision estimate for the first 382 
Exeter Universal stems after 22.8 years with 40 THRs at risk, using Kaplan-Meier (Petheram et al., 
2016). This estimate of revision is higher than our prediction, however this is likely to be because 
27% of THRs were performed for indications other than OA and different cups (Exeter metal back, 
Exeter concentric, Ogee and Muller) were used compared to our study. Apart from the study by 
Wroblewski et al., all these studies report survival from much smaller cohorts of THRs than our 
analyses.  
The published work most relevant to our study, is that of Clarke and colleagues in the Technology 
Assessment Report commissioned by the NIHR HTA Programme on behalf of NICE (Clarke et al., 
2013). Clarke and colleagues used NJR data from the start of the database to 1st March 2012 to model 





THR records which represented 62% of the NJR cohort at that time. The patients were included based 
on the class of THR implanted, these were:  
A. Cemented stem with metal head and cemented polyethylene cup  
B. Cementless stem with metal head and cementless cup with polyethylene liner  
C. Cementless stem with ceramic head and cementless cup with ceramic liner 
D. Cemented stem with metal head and cementless cup with polyethylene liner  
E. Cemented stem with ceramic head and cemented polyethylene cup 
Extrapolated survival at 20, 30 and 50 years were estimated with several commonly used survival 
models, looking at subgroups of patients by age, sex and THR class as defined above. Classes A, D 
and E (above) are relevant to the THRs in our study based on the PEOC database. Clarke et al.’s 
estimates of all cause construct revision modelled using the bathtub method (uncontrolled for age and 
gender), for these three classes were 7.9%, 8.4% and 5.2% at 20 years and 15.6, 16.5% and 9.9% at 
30 years respectively. In our study, the estimates using our unrestricted dataset (all cups) were similar 
at 8.0% (95% CI 7.2, 8.9) at 20 years and 13.7% (95% CI 11.9, 15.8) after 30 years. In our study, 
using only the constructs shown to be generalisable to the rest of the country, these estimates 
(modelled for a 68-year-old female patient) were 4.3% (95% CI 3.3, 5.8) at 20 years and 6.5% (95% 
CI 4.5, 9.4) at 30 years. As with the case-series, our predicted results appear to be better than those 
predicted by Clarke and colleagues. Confidence intervals were not provided by Clarke and colleagues 
for these estimates. The best explanation for the difference is that our analyses are solely based on 
THRs using an Exeter stem, compared to Clarke et al.’s analyses using all prostheses in the NJR 
within each respective class. This is supported by the lower THR revision rate when using Exeter 
stems exclusively, observed in Chapter 3 of this thesis. Recent work by Deere and colleagues 
demonstrates variation in the survival between different constructs and the Exeter stem is frequently 





In general, we have shown a low revision rate for all THRs in this study compared to existing 
literature, including our recent meta-analysis of case-series and registry reports (Evans et al., 2019). 
The results of this study should be even more reassuring for the 128,843 patients in the NJR who have 
one of the three THR constructs that we predict to demonstrate only 7.5% all cause construct revision 
after 30 years. Our estimates are more optimistic than the only other long-term predictions of THR 
survival made using UK data (Clarke et al., 2013) and we believe this is due to variation in survival 
between different prostheses. Policy makers need to decide if a benchmark should be set according to 
what is achievable using all prostheses or change the benchmark, both at 10 years and beyond, to 
reflect the standards that can be achieved with the use of prostheses known to demonstrate low levels 
of revision. 
4.6.1 Strengths and Limitations 
We were unable to confirm whether the THRs in the PEOC database had been revised outside of 
PEOC or whether patients were still alive, as the database is not linked to national records; this is the 
major potential weakness of this research. There were 6,230 THRs performed in PEOC and recorded 
in the NJR up to 31st December 2017 (Chapter 3). Of these THRs that went on to revision surgery 
(recorded in the NJR), almost all (96%) had their revisions in PEOC suggesting the capture of 
revisions by the PEOC database is high. Although the NJR is a linked database, the recent data quality 
audit suggests that capture of THR revision procedures is only 95% nationally (National Joint 
Registry for England, 2017a), meaning the NJR data may also underestimate revision. Of the 664,761 
(86%) THRs in the NJR that met our inclusion criteria (OA as the only indication, no metal on metal 
bearings), 128,843 (19.4%) used the same stem cup combinations as used in our predictive algorithm. 
These stem cup combinations were used for 99.9% of patients in PEOC suggesting that these 
combinations, or ones that perform equally well, could be used for almost all patients in the NJR. 
Given only 19.4% of patients actually received one of these combinations does however limit the 
generalisability of the findings. The strength of this study lies in the large number of patients (11,100 
with an Exeter Universal or Exeter V40 stem combined with a one of the three contemporary and 





they had incomplete or missing information on exposure or co-variates. It was assumed this data was 
missing completely at random and therefore a complete case analysis was performed of the remaining 
cases.  
The main question that remains unanswered from this research is whether our predictions, based on 
the PEOC database, will hold true. Only time and further analyses of the NJR will tell if the survival 
predictions made in this work are accurate. In the shorter term however, we need to utilise other 
resources to externally validate our predicted estimates. International registries such as Australia, New 
Zealand and Sweden with high use of Exeter stems and longer follow-up data, may provide a source 
of data to complete this further validation. The current benchmark provided by NICE and supported 
by ODEP, focusses on the survival of one individual part of a THR construct. Further work is needed 
to better assess whether there is interaction between the two components of a THR and therefore 
decide whether benchmarks should be based on the whole THR construct. The observed differences in 
revision between similar constructs (Deere et al., 2019) in addition to the well documented 
implications of metal on metal bearing surfaces (Smith et al., 2012b) suggest the stem and cup are not 
independent, further supporting this theory. 
4.7 Conclusion 
We predict that fewer than 10% of THRs using the protheses identified in this study will need to be 
revised after 30 years. This suggests a reduction in the current survival benchmark should be 
considered. Given the apparent accuracy of our prediction compared to observed NJR data to date, we 
also propose that there should be an extension of the current benchmark to at least 15 years follow-up 
as approximately 95% of patients under 55 years of age currently undergoing THR will live past the 





Chapter 5 Concluding discussion 
5.1 Overview 
At present, the revision rates of different total hip replacement components are benchmarked 
individually and only up to 10 years post implantation. The individual components (or prostheses) that 
make up a THR do not act independently of each other and 95% of patients under 55 years of age 
undergoing THR will live for more than 10 years following their primary surgery meaning that the 
current systems used could be improved to be more accurate and of interest to patients. This thesis has 
first sought to provide an estimate of longer-term revision rates of THRs by assessing current publicly 
available evidence. I have then analysed a single, long-term single centre database, developing a 
predictive algorithm that can be applied to national registry data with an aim of guiding future 
benchmarks up to 30 years post-operatively. I have considered the THR as a construct, rather than its 
individual components independently, and focused on all cause revision to provide information that is 
relevant and of interest to patients. 
5.2 Summary of findings 
This thesis comprises three main bodies of work. Firstly, I have drawn together existing evidence 
from published case-series and national arthroplasty registries, reporting the long-term survival of 
total hip replacement constructs, to provide a cumulative estimate of survival. I then compared the 
survival of THRs implanted in a single, exemplar centre to the rest of the country; thereby 
demonstrating that the “better than expected” survival achieved in this unit is due to prosthesis choice 
rather than other local factors. This suggests that survival analyses of a long-term database held in this 
unit are generalisable to the rest of the country, assuming the same prostheses are used. Finally, I have 
used this long-term database to make predictions of THR survival for patients who have an 
arthroplasty recorded in the NJR.  
Until the ultimate goal, that all patients undergoing THR experience pain relief and improved function 





will remain an important and much researched subject. Differences between prostheses clearly exist, 
notably in survival patterns and both surgeons and patients should be aware of this when deciding 
whether to proceed with surgery and planning the operation.  
5.2.1 Long-term survival of total hip replacements, a systematic review and meta-analysis 
This thesis presents the first published attempt to provide a simple and generalisable answer to the 
commonly asked question “How long will my hip replacement last?”. Through a systematic review 
and meta-analysis of both published articles and national arthroplasty registers with greater than 15 
years of follow-up, we estimate that 58% of total hip replacements will last 25 years. We also 
observed a relative overestimation of THR survival in journal articles compared to analyses of 
national registry data. 
5.2.2 Generalisability and reproducibility of survival estimates from an exemplar centre 
It has previously been suggested that the results of single centre case-series, particularly those from an 
prosthesis designer (originator) centre may not be generalisable to the rest of the world (Bedair et al., 
2013). This could be due to either over-reporting of survival or local, technical expertise. Using NJR 
data, we have compared the all cause, construct revision rate of THRs implanted in an originator 
centre with exemplar results, to the rest of the country. After adjustment for age and gender, by means 
of flexible parametric survival modelling, we were unable to demonstrate a difference in the survival 
of THRs between the two groups, if the same prostheses were used. This suggests that analyses of the 
long-term PEOC database are generalisable to the rest of the country, assuming use of the same 
prostheses. Given the statistically “better than expected” survival results seen in this exemplar unit, 
compared to other units in the country as reported in the NJR annual report, I also suggest that the 
better survival is a prosthesis effect and not due to technical or process differences. This has the 
implication, that if other centres were to adopt the same prosthesis decisions made in the exemplar 





5.2.3 Creation of prognostic model 
The PEOC database contains usable records for 18,144 THRs performed at the Royal Devon & Exeter 
NHS Foundation Trust, Wonford between 1st January 1988 and 31st December 2017. We employed 
flexible parametric survival modelling to create an algorithm based on this database, adjusted for age 
and gender, we then used this model to predict the revision rate of THRs in all patients with NJR 
records of a primary THR for OA as the only indication. This prediction of 6.5% (95% CI 4.5, 9.4) all 
cause, construct revision at 30 years, is what we expect we would see if all THRs in the NJR were 
made of the same components as those implanted in PEOC. 
5.2.4 Summary 
The current NICE benchmark for THR individual prostheses (considered in isolation) is a revision 
rate of 5% at 10 years. Evidence synthesis of available national registry data suggests 42% of hip 
replacements have been revised after 25 years. My predictive model, developed from data in the 
single centre PEOC dataset, suggests that if all THRs were comprised of the same prosthesis 
combinations as PEOC; 5.4% (95% CI 3.9, 7.5) would be revised after 25 years.  
5.3 Strengths and limitations 
5.3.1 Strengths 
The main strength of this work sits in the high number of patients included. All elements of this thesis 
use national registry data which gives the precision brought by quantity. The smallest subset of 
patients reported occurs in the analysis of THRs performed at PEOC in Chapter 3. Even this smallest 
group reports on over 6,000 patients with 655 hips at risk after 10 years. Another strength is the near 
absence of selection bias in the use of prostheses in PEOC. All but three of the 6,230 THRs reported 
in Chapter 3 used the same femoral stem. This policy of using the same femoral prosthesis regardless 
of age, gender and morphology means there is negligible selection bias from this dataset. Although 
the number of acetabular components used is very small, with only three cups comprising 99% of 





bias. That is why results were reported for all THRs together and did not attempt to separate just those 
with a cemented cup. 
5.3.2 Limitations 
Each individual study in this thesis has its own unique limitations and it is important that these are 
considered when interpreting both the results and the conclusions drawn from this work. There are 
however some common limitations that are common to most elements of this thesis. 
5.3.2.1 Use of survival as an outcome 
The greatest weakness of this work, and indeed all research based on analysis of the survival of 
orthopaedic prostheses, is the use of prosthesis revision as a binary marker of failure. Revision of a 
prosthesis (as recorded on a registry) is both clear and quantifiable and as a result, is frequently used 
as an outcome measure. Revision does not however, account for those operations that a patient may 
class as a failure but have not been revised. Some potential reasons for this situation may be: not 
identifying the patient with a “failure”, patients being unwilling to undergo further surgery, co-
morbidities preventing further operation, not linking the revision operation to the primary or operative 
intervention for a failure that is not identified in the registry, e.g. fixation of a fracture around a THR 
without revision of the prosthesis. All these situations will lead to the underestimation of true revision 
rates in our study population. The choice of endpoint is also very important in survival analysis. All 
elements of this thesis are based on an endpoint of revision of any part of the THR construct for any 
reason, as guided by the patient involvement group at the University of Bristol. Although we have 
used a consistent endpoint, it is important for the reader to be aware that evidence from other sources 
may not and this must be considered when making comparisons.  In addition to these technical 
reasons, the success of a hip replacement is not purely defined by how long it remains in situ. To fully 
assess the impact of different THR constructs on a patient’s life, it is also important to assess 
measures of pain and quality of life, typically with PROMS. In an ideal world a composite measure of 
PROMS and survival would allow the best comparison of THR constructs, however, at present this 





Whilst the use of revision as an outcome is a limitation, if we recognise this in our interpretation of 
results, research based around survival as an outcome can still provide valuable information to 
patients and health care professionals. Whilst it is only one metric that can be measured, it is an 
important one with general health and specific joint consequences for the patient if revision is 
required. 
5.3.2.2 Variation in survival between prostheses 
In 2017, there were 822 different combinations of stem and cup implanted in primary THRs carried 
out in England, Wales, Northern Ireland and the Isle of man as recorded in the NJR. The figures in the 
results section of Chapter 1 demonstrate the differences in survival of different prosthesis 
combinations. These however are subject to selection bias and cannot be taken as definitive evidence 
of variation between prosthesis combinations. A recent article by Deere and colleagues has 
demonstrated these differences more clearly after stratifying by patient age and gender (Deere et al., 
2019). The results presented in both Chapter 3 and Chapter 4 are based on three combinations of stem 
(one stem) and cup (three cups). Whilst these prosthesis combinations are used in over 99% of THRs 
performed at PEOC, this practice may not be replicable in other units due to technical or logistic 
reasons such as surgeon training or prosthesis procurement contracts. The Exeter V40 stem is the 
most commonly implanted in the NJR and as such, most surgeons should have been exposed to 
implantation techniques for this or similar stems during training. This thesis has assumed no selection 
bias in the patients operated at PEOC and more importantly that other units could change practice to 
these prosthesis combinations. It is also worth noting that whilst these are the combinations used for 
demonstration in this thesis, other combinations of prostheses may achieve similar, or even better 
survival results. 
5.3.2.3 Residual confounding 
The adjusted analyses in this thesis have used patient age and gender (at the time of surgery) as co-
variates. Age and gender are strong confounders of revision and as such are used as co-variates for the 





(e.g. OA, rheumatoid arthritis or trauma) is also an important confounder. This thesis restricted NJR 
analyses to THRs performed solely for OA in an attempt to remove indication from the equation but 
in reality, OA is a spectrum of disease and restriction will not remove all confounding. In addition to 
age, sex and indication there are more factors that may confound the association between the type of 
THR construct and all cause construct revision. These may include case complexity and other patient 
specific factors such as co-morbidities, body mass index (BMI) and socio-economic status (SES), 
(Mouchti et al., 2018). These are much harder to reliably quantify with the use of NJR data. Case 
complexity is hard to objectively quantify and in early versions of the NJR minimum data set (MDS) 
form some surgeons reported all cases as complex. Variables such as American Society of 
Anesthesiology (ASA) score and BMI may be missing or not accurately recorded and are therefore 
less reliable. The NJR has used seven different MDS forms to collect data on primary THRs so far 
and not all of these have contained BMI as a variable, which explains the missing data. It is possible 
to submit data to the NJR whilst not completing all data fields and surgeons may be more likely to 
complete the form for higher BMI and ASA scores than those patients deemed lower risk. Had we 
included ASA into analyses this still may not have accounted for the fact that as patients age, they 
develop increasing numbers of co-morbidities that may have an impact on the survival of THRs. The 
interaction effect between age and co-morbidities is also hard to quantify; i.e. do co-morbidities have 
a larger impact on THR survival in older compared to younger patients? We were unable to include 
SES in our models as this would have resulted in excluding all patients operated outside of England. 
We were also limited by the fact that the Exeter database and the NJR did not contain the same 
variables. Including a variable that is only present in one of these databases would have precluded us 
from making the out of sample estimates seen in Chapter 4.  
In summary, whilst indication, age and gender are likely the most important confounders, there may 
be others that play an important role and were not built into the models in this thesis. This may result 
in residual confounding that could be a source of further investigation. This residual confounding may 
result in either over or under-estimation of long-term survival, however given consistency with both 





5.4 Comparison to the existing literature 
5.4.1 Long-term survival of THRs, a systematic review and meta-analysis 
Prior to this work, overall reports of THR survival were generally limited by duration of follow-up, to 
single prostheses, certain modes of failure or to certain classes of THR. The estimates of long-term 
survival, produced in Chapter 1, were largely in agreement with the work by Bayliss and colleagues 
using the CPRD dataset but report the results of a far greater number of patients (Bayliss et al., 2017). 
This study is the first of its kind using registry data, further work may add greater geographical 
coverage and therefore generalisability as well as greater precision. At the time of writing, survival 
estimates for individual constructs are not available in all annual reports for registries with greater 
than 15 years of THR follow-up. 
5.4.2 Generalisability and reproducibility of survival estimates from an exemplar centre 
A large proportion of published literature on survival of THRs originates from the centres that design 
prostheses. The reports from these centres have been criticised as not being generalisable to the rest of 
the target population, suggesting that other centres may not be able to achieve these results (Bedair et 
al., 2013). Our results suggest, that this is not the case for this prosthesis and that the difference 
between units is due to prosthesis selection rather than a centre effect. As far as we are aware, this has 
not been reported previously. 
5.4.3 Creation of prognostic model 
The main comparator for this study is a body of work produced by Clarke and colleagues as part of 
the National Institute for Health Research, Health Technology Assessment programme 11/18 (Clarke 
et al., 2013). This document provides predicted 30-year survival estimates (based on nine-year NJR 
data) for different classes of THR. We adopted a different approach to Clarke by employing an 
exemplar database with longer follow-up as the basis for our predictive algorithm as well as 
principally using flexible parametric survival modelling. The predictions we make, based on the 





at 30 years. These differences may be secondary to restricted prosthesis selection but differing 
methods and reporting of results must also be noted. 
5.5 Implications and recommendations 
Small changes in THR revision rates may have a large effect on the absolute number of patients 
requiring revision surgery because of the high number of THRs implanted annually. In view of this, 
surgeons, researchers and policy makers all have a responsibility to patients to provide stringent, yet 
realistic benchmarks for THR survival.  
The recommendations from this thesis, regarding the long-term benchmarking of THRs comprise 
three main parts: timing of benchmarks, potential lowering of the acceptable revision rate and 
consideration of the stem/cup combination as one entity rather than as individual components. 
5.5.1.1 Timing of benchmarks 
The existing NICE benchmark states that fewer than 5% of THR components should be revised after 
10 years. We have demonstrated from our review of the literature that 58% of THRs last 25 years. 
With many patients expecting and relying upon their THR to last longer than the existing 10-year 
benchmark, it would be helpful to extend the benchmark to reflect this. Whilst the prediction in this 
thesis extends to 30 years, providing benchmarks out this far is unlikely to be helpful. If 
surgeons/units are unable to assess themselves and their prosthesis selections against benchmarks, 
then there is little point in the benchmarks existing. In April 2019, the NJR will have a potential 
follow-up of 16 years on its first patients, we therefore recommend that the NICE guidelines are 
updated to provide at least a 15-year benchmark as well as potentially one at 20 years. 
5.5.1.2 Lowering of acceptable revision rate  
The current UK benchmark is partly based upon work by the Warwick group published by Kandala 
and colleagues (Kandala et al., 2015). Their article predicted 10-year revision estimates based on nine 
years of NJR data. They attempted to include as many THRs as possible in their analyses and ended 





methods and bearings. Given the variation in THR survival according to the construct used recently 
demonstrated by Deere and colleagues, we suggest that a benchmark should not be set at a level that 
encompasses as many THRs as possible but rather one that encourages best practice. In Chapter 3, we 
suggest that the “better than expected” survival, demonstrated by an exemplar centre may be 
replicated simply using the same prosthesis selections as that centre or prosthesis selections that have 
been demonstrated to not be worse than the exemplar centre. In view of this, if the benchmark 
revision rate were lowered to reflect the survival seen by the best performing constructs then by 
simply using these, most centres may achieve the benchmark.  
Chapter 4 of this thesis suggests if all THRs in the NJR behaved the same as those implanted at PEOC 
then only 2.2% (95% CI 1.8, 2.7) would be revised at 10 years. This prediction, which has been 
validated against observed NJR data, supports a lowering of the benchmark at 10 years to 3%. Whilst 
this change may appear small, the impact on the absolute number of revisions on a national scale 
would potentially be large. The 15-year revision rate predicted by our algorithm (and validated on 
observed data) is 3.3% (95% CI 2.6, 4.1) suggesting that the current benchmark of 5% revision could 
be moved back to 15 years.  
The aim of changing the benchmark would be to influence surgeons to use prostheses with proven 
better survival than the majority of those currently used. Despite the conclusion in Chapter 3, that 
survival is prosthesis driven rather than surgeon driven, the effect of changing the practice of many 
surgeons is unknown and this requires further research. It remains possible that better surgeons choose 
better prostheses and that there is some selection bias in our results. Forcing all surgeons to use 
specific prostheses could have the undesired effect of reducing the overall survival of the previously 
better performing constructs.  
5.5.1.3 Use of the construct for benchmarking 
The NICE guidance, from which the UK benchmark is drawn, specifies that each individual 
component of a THR should demonstrate under 5% revision at 10 years; no reference is made to the 





revision and 5% of the acetabular components in a particular construct also fail, at the individual 
prosthesis level, the revision rate may be up to 10% depending upon the definition of revision (any 
part of a construct or only the specific prosthesis). Ignoring the overall construct revision rate, NICE 
assume there is no interaction between the femoral stem and acetabular component that may influence 
survival. In Chapter 3, I demonstrated that survival of the Exeter V40 femoral stem across the whole 
country was heavily reliant on the choice of acetabular component, this effect was also demonstrated 
(albeit at a local level) in Chapter 4. The Orthopaedic Data Evaluation Panel (ODEP) collate 
manufacturer provided information and present a summary to patients and surgeons to help them 
make prosthesis choices that meet NICE guidelines. At present ODEP do not publish survival ratings 
for construct combinations. Given the influence of the acetabular component on overall survival 
demonstrated in this thesis as well as the variation in construct survival recently seen by Deere and 
colleagues; we suggest that benchmarks may need updating to guide the choice of overall construct 
rather than just individual components. Further work is needed however, to confirm whether two 
individual components which both meet the NICE benchmark ever, when combined, demonstrate a 
revision rate higher than 5%.  
5.6 Future research 
5.6.1 Collaborative registry analyses of THR survival  
The estimates produced in Chapter 1 are the first of their type and provide a simple answer to the 
question “How long does a hip replacement last?”. The conclusions, however, are based almost 
entirely on results of the Finnish Arthroplasty Register. This is because some of the registries with the 
longest follow-up (such as Sweden and Norway) do not include survival estimates for individual 
stem/cup construct combinations in their annual report. Collaboration between international registries 
to provide summary estimates for specific constructs will add greater precision and generalisability to 





5.6.2 What would be the effect of everyone using the same three constructs? 
We suggest in Chapter 3, that the observed all cause construct revision rate of certain constructs is 
lower than the overall revision observed in the NJR. We have also suggested that the constructs used 
in 99% of cases at PEOC can be used for most cases, given their exclusive use in this reasonably 
high-volume centre. Given this, it would be interesting to investigate how many revisions could be 
avoided if all surgeons used these prosthesis combinations. It would also be interesting to assess the 
potential cost implications of such a change. An attempt to do this was published in 2012 (Griffiths et 
al., 2012), however with more data available now, updated research in this area would be of great 
interest.  
5.6.3 Analysis of other centres using very few construct combinations. 
The conclusion drawn in Chapter 3, that better unit revision rates are a result of prosthesis selection is 
based upon the results of one centre. It would be interesting to see if a similar effect is seen in other 
centres that use the same prostheses almost exclusively. A time series analysis of a centre that has 
made a sudden decision to change to the constructs we suggest, would also be of use. These analyses, 
whilst relatively simple, require further permission from the NJR for use of the available data to 
conduct these analyses. 
5.6.4 Validation of the prognostic model against other national arthroplasty registries 
We have validated the predictive algorithm using observed NJR data up to 14.2 years post-surgery in 
Chapter 4. The prostheses used for the formation of the algorithm are used worldwide and in countries 
with longer follow-up in their respective national registries. Validation of the algorithm against other 
datasets such as Swedish, Australian or New Zealand joint replacement registers will give us a better 






5.6.5 Does the revision rate of a THR depend on an interaction between stem and cup? 
We have previously discussed the potential for the use of a construct benchmark rather than the 
existing one which looks at individual elements of the THR. Whilst evidence from this thesis and 
recent literature support this, it is a relatively novel concept. A formal analysis of NJR data comparing 
the all cause construct revision of frequently used stems with different cups, having adjusted for 
patient factors, would give further information on this subject. It would be useful to know if there are 
any combinations of ODEP 10A* prostheses that when combined, exhibit a revision rate of greater 
than 5% at ten years. 
5.7 Concluding remarks 
This thesis has attempted to improve the evidence regarding the benchmarking of THR prostheses in 
the UK. The principal aim was to predict the long-term (greater than 15 year) survival of THRs 
implanted in England and Wales and this has been achieved. Time and future studies will hopefully 
provide further validation of these predictions. 
Benchmarks exist to set minimum acceptable performance standards, ensuring that as many patients 
as possible receive optimum standards of care. With regards to survival of hip replacements, there is 
growing evidence of variation between prostheses that all fall within the current benchmark. To 
ensure as many patients as possible receive gold standard care we support the lowering of the 
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Appendix 5 - Search strategy formatted for Medline on Ovid Silver Platter 
Hip replacement 
Hip Prosthesis/ OR Arthroplasty, Replacement, Hip/ OR  
(hip adj2 arthroplast$.mp) OR (hip adj2 replacement?.mp) OR  
THA.mp OR THR.mp OR (TJR$.mp AND hip$.mp) 
AND 
Survival 
Prosthesis Failure/ OR Survival Analysis/ OR  
cox.mp OR proportional?hazard?.mp OR proportional hazard?.mp OR  
cumulative?incidence?function.mp OR cumulative incidence function.mp OR CIF.mp OR  
failure.mp OR  
survival.mp OR survivor?ship.mp OR  
revision?.mp OR  
re?operation.mp OR re operation.mp OR 
Kaplan?meier.mp OR Kaplan meier.mp OR KM.mp OR 
product?limit?method.mp OR product limit method.mp 
AND 
Case-series 
exp Cohort Studies/ OR  
follow?up.mp OR follow-up.mp OR series.mp OR cohort.mp OR  
registry.mp OR registries.mp 
AND 
Long-term (minimum 15 years) 
long?term.mp OR long-term.mp OR 
 (1#* adj1 year?.mp) OR (2#* adj1 year?.mp) OR (3#* adj1 year?.mp) OR (4#* adj1 year?.mp) 







Appendix 6 - Articles contributing to meta-analysis 
Author Year of 
publication 








Abdel, M. P.1 2016 40.0 72.0 67.0 77.0 
Anseth, S. D.2 2010 20.0 84.7 74.7 91.5 
Belmont, P.J.3 2008 20.0 74.3 67.6 81.0 
Berry, D. J.4 2002 15.0 89.8 88.3 91.2 
Berry, D. J.4 2002 20.0 84.1 82.2 85.9 
Berry, D. J.4 2002 25.0 80.9 78.4 83.0 
Boyer, B.5 2011 15.0 81.4 76.2 86.6 
Boyer, B.5 2011 20.0 75.4 69.2 81.5 
Boyer, B.5 2011 22.0 73.9 67.3 80.6 
Buckwalter, A. E.6 2006 25 80 73 87 
Busch, V. J.7 2012 17.0 89.0 85.0 93.0 
Callaghan, J. J.8 2000 27.0 76.0 63.0 89.0 
Callaghan, J.J..9 2009 35.0 78.0 70.0 86.0 
Clarius, M.10 2010 17.0 75.0 65.0 85.0 
Clarius, M.11 2010 17.0 49.0 41.0 57.0 
Corten, K.12 2011 15.0 66.0 61.4 70.6 
Corten, K.12 2011 20.0 47.9 41.3 54.5 
Corten, K.12 2011 15.0 79.5 75.7 83.3 
Corten, K.12 2011 20.0 69.4 64.3 74.5 
Cruz-Pardos, A.13 2017 20 84.1 73.91 94.29 
Devitt, A.14 1997 20.0 75.0 66.0 84.0 
El Masri, F.15 2010 17.0 90.5 84.2 96.8 
Georgiades, G.16 2009 25 51 39 62 
Georgiades, G.16 2009 30 47 35 59 
Gerritsma-Bleeker, C. L.17 2000 15.0 91.0 86.0 97.0 
Gerritsma-Bleeker, C. L.17 2000 17.0 91.0 86.0 97.0 
Gerritsma-Bleeker, C. L.17 2000 22.0 85.0 75.0 95.0 
Hartofilakidis, G.18 1997 16.0 78.0 74.0 82.0 
Hartofilakidis, G.18 1997 18.0 73.3 65.5 81.1 
Hartofilakidis, G.18 1997 20.0 67.0 58.0 76.0 
Hartofilakidis, G.19 1997 17 73 67.7 78.3 
Hartofilakidis, G.19 1997 20 60 51.7 68.3 
Hartofilakidis, G.19 1997 17 86 82.5 89.5 
Hartofilakidis, G.19 1997 20 80 71.7 88.3 
Hartofilakidis, G.20 2015 20.0 73.0 67.2 78.8 
Hartofilakidis, G.20 2015 30.0 53.0 43.2 62.8 
Ihle, M..21 2008 19.8 79.7 70.0 88.0 
Kang, B. J.22 2015 15.9 98.9 96.7 100.0 
Kawamura, H..23 2016 24.6 87.0 77.8 92.7 
Keener, J. D.24 2003 30.0 60.0 53.0 67.0 





Kolb, A..26 2012 20.0 65.0 55.0 73.0 
Lass, R.27 2014 18.8 87.0 82.6 91.4 
Madey, S.M..28 1997 15.0 86.0 82.0 90.0 
Mullins, M. M.29 2007 15.0 89.5 87.8 91.2 
Mullins, M. M.29 2007 20.0 84.1 81.3 86.9 
Mullins, M. M.29 2007 25.0 77.4 74.2 80.6 
Mullins, M. M.29 2007 30.0 73.3 67.2 79.4 
Nercessian, O. A.30 2005 15.0 84.2 81.4 87.0 
Nercessian, O. A.30 2005 20.0 66.2 60.5 71.9 
Neumann, L.31 1994 15.0 91.8 88.0 95.6 
Neumann, L.31 1994 20.0 89.3 84.6 94.0 
Petsatodis, G. E.32 2010 20.8 84.4 56.0 100.0 
Reigstad, O.33 2008 18.0 88.0 80.0 96.0 
Schulte, K.R.34 1993 20.0 80.0 72.0 88.0 
Skutek, M.35 2007 25.0 83.0 77.0 89.0 
Sochart, D. H.36 1998 25.0 65.0 54.0 76.0 
Sochart, D. H.37 1997 20 67 61 74 
Sochart, D. H.37 1997 25 65 58 72 
Suckel, A.38 2009 17.0 97.0 94.0 99.0 
Toni, A.39 2017 15.0 93.2 89.0 97.3 
Trebse, R.40 2005 15.0 48.0 44.0 52.0 
Warth, L.C.41 2014 35.0 57.6 45.7 69.5 
Wroblewski, B. M.42 2002 15.0 84.7 82.4 87.1 
Wroblewski, B. M.42 2002 20.0 74.2 70.5 78.0 
Wroblewski, B. M.42 2002 25.0 65.6 58.4 72.8 
Wroblewski, B. M.42 2002 27.0 55.3 45.5 60.5 
Wroblewski, B. M.42 2002 30.0 47.0 29.4 64.7 
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Appendix 8 - Forest plot of estimates for reported survival of constructs used more than 250 times in 2016 from registry 




































Appendix 9 – Number of hips at risk for each analysis at each time point 
 Number of THRs at risk (years post op) 
3 5 7 10 13 
All THRs implanted in all other units 422,263 285,468 172,630 61,395 8111 
All THRs implanted in exemplar centre 4,123 2,622 2,031 655 69 
THR constructs using a cemented stem implanted in all other units 245,755 171,881 112,251 44,610 6412 
THR constructs using a cemented stem operated on at exemplar centre 4,122 2,622 2,031 655 69 
THR constructs using an Exeter V40 stem implanted in all other units 147,596 10,051 62,715 22,465 2336 
THR constructs using an Exeter V40 stem implanted in exemplar centre 4,121 2,621 2,030 655 69 
THR constructs using constructs used at exemplar centre implanted in all other units 86,842 54,445 32,307 10,171 689 
THR constructs using constructs used at exemplar centre implanted in exemplar 
centre 
4,121 2,621 2,030 655 69 
THR constructs using an Exeter V40 stem implanted in all other units censoring 
revisions for instability and infection  
147,596 100,051 62,715 22,465 2336 
THR constructs using an Exeter V40 stem implanted in exemplar centre censoring 
revisions for instability and infection  
4,121 2,621 2,030 655 69 
THR constructs using constructs used at exemplar centre implanted in all other units 
censoring revisions for instability and infection  
86,842 54,445 32,307 10,171 689 
THR constructs using constructs used at exemplar centre implanted in exemplar 
centre censoring revisions for instability and infection  

























































Appendix 17 - Predicted probability of revision of THRs in the NJR, based on algorithm derived from hips using an Exeter 
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Appendix 18- Graph comparing algorithms derived from Exeter V40 stems paired with a generalisable cup and Exeter V40 
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Appendix 20 - Point survival estimates from observed data and prognostic algorithm 
Time point (years) Observed survival 
from PEOC database. 
Number of THRs at 
risk in PEOC database 
Algorithm predicted 
revision rate* 
Observed survival in NJR* 
5 1.3% (95% CI 1.1, 1.5) 6,382 1.3% (95% CI 1.1, 1.5) 1.8% (95% CI 1.8, 1.9) 
10 2.2% (95% CI 1.9, 2.6) 2,451 2.8% (95% CI 2.5, 3.1) 3.4% (95% CI 3.3, 3.5) 
15 3.4% (95% CI 2.7, 4.2) 300 5.3% (95% CI 4.7, 5.9) - 
20 -  8.0% (95% CI 7.2, 8.9) - 
25 -  10.2% (95% CI 9.6 12.2) - 
30 -  13.7% (95% CI 11.9, 15.8) - 
* Algorithm based on THRs using Exeter Universal or Exeter V40 stem with all cups, modelled for 68-year-old female patient 
 
